

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

**A multicentre, placebo-controlled, randomised, double-blind, parallel-group study investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation (CONST-PD): The protocol**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054129
Article Type:	Protocol
Date Submitted by the Author:	04-Jun-2021
Complete List of Authors:	Hatano, Taku; Juntendo University, Neurology Oyama, Genko; Juntendo University Faculty of Medicine, Department of Neurology; Juntendo University Faculty of Medicine Shimo, Yasushi; Juntendo University School of Medicine, Department of Neurology Ogaki, Kotaro ; Juntendo Urayasu Hospital Nishikawa, Noriko ; Juntendo University Faculty of Medicine Fukae, Jiro ; Juntendo Nerima Hospital Nakamura, Ryota ; Juntendo Urayasu Hospital Kurita, Naohide ; Juntendo Urayasu Hospital Tsunemi , Taiji ; Juntendo University Faculty of Medicine Oji, Yutaka ; Juntendo University Faculty of Medicine Saiki, Shinji ; Juntendo University Faculty of Medicine Nishioka, Kenya ; Juntendo University Faculty of Medicine Takeshige, Haruka Taniguchi, Daisuke ; Juntendo University Faculty of Medicine Ogawa, Takashi; Juntendo University School of Medicine, Neurology Kamo, Hikaru ; Juntendo University Faculty of Medicine Eguchi, Hiroto ; Juntendo Nerima Hospital Fuse, Atsuhito ; Juntendo Nerima Hospital Nakajima, Asuka ; Juntendo Nerima Hospital Kano, Masayoshi ; Juntendo Nerima Hospital Nakajima, Sho ; Juntendo Urayasu Hospital Yanagisawa, Naotake; Juntendo University Hospital Hattori, Nobutaka ; Juntendo University Graduate School of Medicine, Neurology
Keywords:	Parkinson-s disease < NEUROLOGY, Motility disorders < GASTROENTEROLOGY, Clinical trials < THERAPEUTICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 **A multicentre, placebo-controlled, randomised, double-blind, parallel-group study**  
7  
8  
9 **investigating the efficacy and safety of elobixibat, an ileal bile acid transporter**  
10  
11  
12 **inhibitor, in patients with Parkinson's disease with chronic constipation**  
13  
14  
15 **(CONST-PD): The protocol**  
16  
17  
18  
19  
20

21 Taku Hatano<sup>1</sup>, Genko Oyama<sup>1</sup>, Yasushi Shimo<sup>2</sup>, Kotaro Ogaki<sup>3</sup>, Noriko Nishikawa<sup>1</sup>,  
22  
23 Jiro Fukae<sup>2</sup>, Ryota Nakamura<sup>3</sup>, Naohide Kurita<sup>3</sup>, Taiji Tsunemi<sup>1</sup>, Yutaka Oji<sup>1</sup>, Shinji  
24  
25 Saiki<sup>1</sup>, Kenya Nishioka<sup>1</sup>, Haruka Takeshige-Amano<sup>1</sup>, Daisuke Taniguchi<sup>1</sup>, Takashi  
26  
27 Ogawa<sup>1</sup>, Hikaru Kamo<sup>1</sup>, Hiroto Eguchi<sup>2</sup>, Atsuhito Fuse<sup>2</sup>, Asuka Nakajima<sup>2</sup>, Masayoshi  
28  
29 Kano<sup>2</sup>, Sho Nakajima<sup>3</sup>, Naotake Yanagisawa<sup>4</sup>, Nobutaka Hattori<sup>1</sup>  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<sup>1</sup> Department of Neurology, Juntendo University Faculty of Medicine, 2-1-1 Hongo,  
Bunkyo-ku, Tokyo 113-8421, Japan

<sup>2</sup> Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai,  
Nerima-ku, Tokyo 177-8521, Japan

<sup>3</sup> Department of Neurology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka,  
Urayasu, Chiba 279-0021, Japan

<sup>4</sup> Juntendo Clinical Research and Trial Center, Juntendo University Hospital, 3-1-1,

1  
2  
3  
4  
5  
6 Hongo, Bunkyo-ku, Tokyo, Japan  
7  
8  
9  
10

11  
12 Correspondence to: Taku Hatano; [thatano@juntendo.ac.jp](mailto:thatano@juntendo.ac.jp) and Nobutaka Hattori;  
13  
14

15 [nhattori@juntendo.ac.jp](mailto:nhattori@juntendo.ac.jp)  
16  
17  
18  
19  
20

21 **Word count:** 3431  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ABSTRACT

### Introduction

Chronic constipation can worsen the quality of life (QOL) of patients with Parkinson's disease (PD). Elobixibat, an ileal bile acid transporter inhibitor, is known to be a useful laxative, but whether it has an effect on chronic constipation in PD patients remains unclear. Therefore, we have planned a placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of elobixibat in PD patients with chronic constipation.

### Methods and analysis

The study will consist of 2-week observation and 4-week treatment periods. Patients diagnosed with clinically established PD will record the status of spontaneous bowel movements and use of rescue medications/concomitant medications in a Bowel Movement Diary from the start of the observation period at Visit 1 (Week -2). At Visit 2 (Week 0), patients will be assessed for final registration based on the Diary records and physical examinations, and then allocated to either the elobixibat or placebo group. Records of daily intake of the investigational drug will be included in the Diary. Patients will undergo laboratory tests and answer constipation-related, PD-related, and QOL-related questionnaires at Visit 2 and Visit 4 (Week 4). Subjective symptoms and objective findings will be collected at Visits 2, 3 (Week 2), and 4. Since patients' motor function might be improved by treatment of constipation, the use of dopamine preparations will also be monitored. Bowel movement data and other parameters will be compared between the elobixibat and placebo groups. Safety information will be collected as adverse events, while specifically focusing on

1  
2  
3  
4  
5 those occurring in association with study conduct.  
6  
7  
8  
9

### 10 **Ethics and dissemination**

11  
12 This study will be conducted in accordance with the Helsinki declaration, the Clinical  
13  
14 Trials Act of the Japan Ministry of Health, Labour and Welfare, and related laws and  
15  
16 regulations. All patient data will be anonymized to protect privacy and used only for the  
17  
18 study purpose.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Registration number of this study:** JPRN-jRCTs031200172 (Japan Primary Registries  
Network)

### 37 **Keywords**

Parkinson's disease, Motility disorders, Clinical trials

### Strengths and limitations of the study

- This study will explore the efficacy and safety of elobixibat versus placebo in PD patients with chronic constipation in a randomised, double-blind manner.
- Given that there is evidence that probiotic/prebiotic fibre, lubiprostone, and macrogol improve chronic constipation in PD patients, this study is expected to provide further evidence to expand treatment options to improve the disease condition and, thereby, the patients' quality of life.
- Because of the short study period (4-week administration), the long-term efficacy and safety of elobixibat may not be clarified.
- Diary data might have limited credibility because they are based on the patients' subjective responses.



## INTRODUCTION

Parkinson's disease (PD) is one of the most common neurodegenerative disorders.

Whereas PD is commonly considered a movement disorder, patients with PD have

many difficulties with non-motor symptoms, such as dementia, anxiety, sleep

disturbance, and autonomic dysfunction.[1] Chronic constipation is one of the common

digestive complications experienced by PD patients even before or at an early stage of

disease progression, with its frequency varying from 7% to 70% depending on the

definition.[2-6] Since long-lasting constipation may decrease quality of life (QOL) and

be occasionally accompanied by life-threatening intestinal perforation and/or megacolon

syndrome, it should be appropriately controlled.[7,8]

Multiple types of laxatives are conventionally available for the treatment of chronic

constipation, including bulk-forming agents such as carmellose sodium and dioctyl

sodium sulfosuccinate, stimulants such as sennoside and sodium picosulphate hydrate,

and osmotic agents such as cathartic salts (magnesium oxide and magnesium sulphate).

While stimulants and cathartic salts have been widely used, stimulants may cause

intractable constipation via drug resistance if used consecutively for a long duration,

and magnesium oxide may cause hypermagnesemia in elderly patients and patients with

kidney malfunction.[9]

1  
2  
3  
4  
5  
6 Recently, in addition to existing osmotic agents (macrogol 4000 often in combination  
7  
8  
9 with electrolytes, movicol, lactulose), new classes of laxatives have been developed for  
10  
11  
12 chronic constipation, including epithelial function transformation drugs (lubiprostone,  
13  
14  
15 linaclotide) and an ileal bile acid transporter (IBAT) inhibitor (elobixibat).

16  
17  
18 However, the evidence for the effectiveness of laxatives either conventional or recently  
19  
20  
21 developed for the treatment of chronic constipation in PD patients is not extensive,  
22  
23  
24 except for macrogol and lubiprostone, a chloride channel-2 activator, which have been  
25  
26  
27 shown to be significantly efficacious over placebo in improving bowel movement  
28  
29  
30 frequency.[10, 11] Although probiotics and prebiotic fibre were also proposed to be  
31  
32  
33 useful for the treatment of PD-related constipation,[12, 13] more evidence for different  
34  
35  
36 classes of laxatives is needed to expand therapeutic options for chronic constipation in  
37  
38  
39 PD patients.

40  
41  
42 Elobixibat is an inhibitor of IBAT, which is expressed in the distal ileum. Bile acids  
43  
44  
45 escape the reabsorption process via the action of this drug and then enter the large  
46  
47  
48 intestinal lumen.[14] The increased levels of bile acids may lead to an influx of water  
49  
50  
51 and electrolytes into the lumen, inducing colonic high-amplitude propagated  
52  
53  
54 contractions (HAPCs). Elobixibat is thus expected to be a novel option for the treatment  
55  
56  
57 of chronic constipation on the basis of its mode of action being totally different from  
58  
59  
60

1  
2  
3  
4  
5  
6 those of the other existing laxatives.[15, 16]  
7  
8

9 We are planning to conduct a study to examine the efficacy and safety of elobixibat in  
10  
11 PD patients with chronic constipation. The superiority of elobixibat over placebo will be  
12  
13 explored in a randomized, double-blind, comparative study during 4-week daily  
14  
15 administration of the drug to eligible patients. The drug will also be evaluated for its  
16  
17 safety and potential impact on the underlying PD condition. This study was approved by  
18  
19 the Ethics Committee of the Juntendo University School of Medicine (J20-009). The  
20  
21 study methodology is detailed in this article.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

## 32 **METHODS AND ANALYSIS**

33  
34  
35 The objective of this study is to explore a novel therapeutic option for chronic  
36  
37 constipation in PD patients.  
38  
39  
40  
41  
42  
43  
44

### 45 **Primary endpoints**

46  
47 The weekly frequency of spontaneous bowel movements with no assistance from rescue  
48  
49 therapies such as bisacodyl suppositories, enema, disimpaction, etc. (see below) will be  
50  
51 recorded during each 7-day segment of the treatment period (Week 0-1 up to Week 3-4;  
52  
53 see Figure 1). Bowel movements observed within 24 hours of suppository use will not  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 be counted. Changes in the frequency at Visit 4 (Week 4) from baseline (Visit 2/Week  
7  
8  
9 0; see Figure 1) will be compared between the elobixibat group and the placebo group.

### 15 **Secondary endpoints**

17  
18 Weekly changes from baseline in the frequency of spontaneous bowel movements and  
19  
20 complete spontaneous bowel movements (i.e., no sensation of incomplete evacuation)  
21  
22 will be assessed throughout the treatment period (Visit 4/Week 4; Figure 1). Changes  
23  
24 from baseline in stool form will also be assessed up to Week 4 using the Bristol  
25  
26  
27 Scale.[17]

28  
29  
30  
31  
32 Use of rescue medication and questionnaire surveys using the Japanese version of  
33  
34 Patient Assessment of Constipation Quality of Life (JPAC-QOL),[18] Movement  
35  
36 Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS),[19]  
37  
38 Parkinson's Disease Questionnaire-39 (PDQ-39),[20] and Euro-Qol 5 dimension – 5  
39  
40 level (EQ-5D-5L)[21,22] will be assessed. The use of dopamine preparations will also  
41  
42 be monitored, since the effectiveness of elobixibat in improving constipation via  
43  
44 increased levels of intestinal bile acids may also improve small intestinal absorption of  
45  
46 the anti-Parkinsonian medications.

47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57 Subgroup analyses will be further performed for these endpoints by patient background

1  
2  
3  
4  
5  
6 and dose of investigational drug.  
7  
8  
9

## 10 11 12 **Overall study design** 13

14  
15 This study is designed as a randomised, double-blind, placebo-controlled, parallel-group  
16  
17  
18 study at 2 academic centres (Juntendo University Urayasu Hospital, and Juntendo  
19  
20 University Nerima Hospital), in which PD patients with chronic constipation will  
21  
22 pre-prandially receive elobixibat (Goofice®; EA Pharma Co., Ltd., Tokyo, Japan) or its  
23  
24 indistinguishable matched placebo once daily for four weeks, and the frequency of  
25  
26  
27 spontaneous bowel movements will be compared between the patients receiving either  
28  
29  
30 elobixibat or placebo. Safety information, including adverse events (AEs) and  
31  
32  
33 discontinuation and interruption of the investigational drugs, will also be collected.  
34  
35  
36  
37

38  
39 The study will consist of two periods, the observation period and the treatment period. It  
40  
41  
42 will be conducted from October 26, 2020 (date of the first announcement in the Japan  
43  
44 Registry of Clinical Trials; jRCT) through September 30, 2022. As seen in Figure 1, we  
45  
46  
47 plan two steps for patient registration, temporary and final. At Week -2 (Visit 1) of the  
48  
49  
50 observation period, PD patients will be provided with the detailed information about the  
51  
52  
53 study. After providing written, informed consent for study participation, they will be  
54  
55  
56 temporarily registered based on the patient definitions (see below). Following the  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 observation period, the patients will be further assessed for study participation at Week  
7  
8  
9 0 (Visit 2). Once none of the exclusion criteria are confirmed to be applicable, the  
10  
11  
12 patients will be finally registered and assigned to either the elobixibat group or the  
13  
14  
15 placebo group in a double-blind manner (Figure 1). The eligible patients will visit their  
16  
17  
18 clinical sites twice more (Visit 3 at Week 2 and Visit 4 at Week 4) during the 4-week  
19  
20  
21 treatment period.  
22

23  
24 A Bowel Movement Diary will be provided at Week -2 (Visit 1, see below) to each  
25  
26  
27 patient, once temporarily registered. The patient will record drug use, bowel movements,  
28  
29  
30 etc. in the Diary daily throughout the study period.  
31  
32

### 33 34 35 36 **Patient definitions**

37  
38  
39 Patients will be diagnosed as having PD in reference to the diagnostic criteria defined  
40  
41  
42 by the International Parkinson and Movement Disorder Society (MDS)[23] and must be  
43  
44  
45 in stages 1 to 4 on the Hoehn and Yahr scale.[24] The diagnosis of chronic constipation  
46  
47  
48 will be made referring to the Rome IV-defined criteria.[25,26] Outpatients aged  $\geq 20$   
49  
50  
51 years at the time of informed consent must have two or more of the following symptoms  
52  
53  
54 related to spontaneous bowel movements from at least 6 months before consent: i)  $< 3$   
55  
56  
57 spontaneous bowel movements per week; ii) straining frequency  $> 25\%$  of defecations;  
58  
59  
60

1  
2  
3  
4  
5  
6 iii) frequency of lumpy or hard stools >25% of defecations; and iv) sensation of  
7  
8  
9 incomplete evacuation >25% of defecations. Patients who meet these criteria will be  
10  
11 temporarily registered, once written, informed consent is provided (Figure 1).  
12  
13  
14  
15  
16  
17

18 A PD patient will be excluded at temporary registration if he/she: has (or is suspected to  
19  
20 have) organic constipation or dyschezia; is unable to use a rescue medication (bisacodyl  
21  
22 10 mg suppositories; Teleminsoft Suppositories® 10 mg, Cox Japan, Tokyo, Japan);  
23  
24 currently has serious kidney dysfunction (creatinine  $\geq 2.00$  mg/dL), serious hepatic  
25  
26 dysfunction (total bilirubin  $\geq 3.0$  mg/dL, or AST or ALT  $\geq 100$  U/L), or serious cardiac  
27  
28 dysfunction; has malignant tumour(s); has a history of hypersensitivity to elobixibat; is  
29  
30 taking bile acid preparations (ursodeoxycholic acid, chenodeoxycholic acid),  
31  
32 aluminium-containing preparations (sucralfate hydrate, aldioxa, etc.), cholestyramine,  
33  
34 colestimide, digoxin, dabigatran etexilate mesylate, or midazolam; has a Mini-Mental  
35  
36 State Examination (MMSE) score[27]  $\leq 26$ ; or is considered ineligible by the  
37  
38 investigator or sub-investigator, hereinafter termed (sub)investigator, for study  
39  
40 participation because of safety concerns, poor protocol compliance, etc. Female patients  
41  
42 will also be excluded if they are pregnant, breastfeeding, or expecting pregnancy during  
43  
44 the study period.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 Patient exclusion is further scheduled at the final registration if one of the following  
7  
8  
9 cases applies to a patient during the 2-week observation period: use of the rescue  
10  
11 medication (bisacodyl 10 mg suppositories)  $\geq 5$  times; use of the rescue medication  
12  
13 within 72 hours post-bowel movement; experience of spontaneous bowel movement  
14  
15 with mushy or watery stool according to Bristol Stool Form Scale (BSFS) type 6 or  
16  
17 7;<sup>[17]</sup> or use of prohibited medications/therapies (see below).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

### 28 **Study procedures and schedule**

29  
30 Registration of study patients and their allocation to the investigational drug will be  
31  
32 performed via an internet-mediated Interactive Web Response System (IWRS). The  
33  
34 (sub)investigator (or study-assigned coordinator) will access the specific website for  
35  
36 patient registration and allocation using a specific ID and password and complete the  
37  
38 necessary information about each anonymized patient. Investigational drug allocation  
39  
40 will be instantly presented for each patient following eligibility judgment. Drug  
41  
42 allocation will be based on a stratified, permuted block method with sex as an allocation  
43  
44 factor.  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 The schedule of this study is shown in Figure 2.

55  
56  
57 The (sub)investigator will give detailed explanations of this study to each PD patient  
58  
59  
60



1  
2  
3  
4  
5  
6 who meets the inclusion criteria but not the exclusion criteria at Visit 1 and then obtain  
7  
8  
9 the patient's written, informed consent on a free will basis. The patient will be informed  
10  
11  
12 that he/she may withdraw his/her consent for any reason and at any time during the  
13  
14  
15 study period. The (sub)investigator will give the eligible patient a temporary  
16  
17  
18 identification code and enter the patient's background in the Eligibility for Temporary  
19  
20  
21 Registration form of the electronic Case Report Form (eCRF; see Figures 1 and 2).  
22  
23  
24 The Bowel Movement Diary and rescue medication (bisacodyl 10 mg suppositories)  
25  
26  
27 will be provided to each patient at temporary registration. The (sub)investigator will  
28  
29  
30 instruct each patient how to complete the required items in the Diary.  
31  
32  
33 At Visit 2, the (sub)investigator will judge the eligibility of each patient for final  
34  
35  
36 registration referring to the exclusion criteria (see above) and enter the background of  
37  
38  
39 qualified patients in the Eligibility for Final Registration form of the eCRF. Once the  
40  
41  
42 patient's eligibility is confirmed, a final identification code will be assigned to the  
43  
44  
45 patient, who will be then allocated randomly to treatment group. The (sub)investigator  
46  
47  
48 will check the final identification code and the allocated investigational drug number for  
49  
50  
51 each qualified patient on the IWRS screen. The specifically numbered drug will be  
52  
53  
54 provided to the patient by the (sub)investigator at Visit 2 and Visit 3 for 2 weeks each  
55  
56  
57 time (3 tablets x 14 days), as described below.  
58  
59  
60

1  
2  
3  
4  
5  
6 The patient will start the 4-week treatment period with once-daily, preprandial intake of  
7  
8  
9 2 tablets of investigational drug (elobixibat 10 mg) or its placebo. One tablet may be  
10  
11  
12 added on the next day if no spontaneous bowel movement is observed during the next  
13  
14  
15 24 hours. If excessive effectiveness or discomfort appears, the dosage may be decreased  
16  
17  
18 at the direction of the (sub)investigator or the patient's judgment. Dose augmentation  
19  
20  
21 from 1 tablet to 3 tablets will not be allowed. Interruption of the investigational drug  
22  
23  
24 due to the occurrence of an AE may be allowed at the direction of the (sub)investigator  
25  
26  
27 or the patient's judgment, but as-needed intake of the drug based on bowel movement  
28  
29  
30 status will not be acceptable. The drug may be restarted at the dose taken immediately  
31  
32  
33 before interruption or at a lower dose. Inappropriately long ( $\geq 7$  consecutive days) or  
34  
35  
36 frequent ( $\geq 3$  days per week during 2 consecutive weeks) interruption of the drug may  
37  
38  
39 lead to discontinuation of the patient from the study at the (sub)investigator's discretion.  
40  
41  
42  
43  
44

#### 45 **Rescue and concomitant medications/therapies**

46  
47  
48 Since this study is primarily planned to explore the efficacy and safety of elobixibat as a  
49  
50  
51 laxative in PD patients, concomitant medications will be used throughout the study  
52  
53  
54 period for parkinsonism except for Duodopa<sup>®</sup> pump therapy (Abbvie Inc., North  
55  
56  
57 Chicago, IL, USA) with levodopa/carbidopa hydrate intestinal gel. Bisacodyl 10 mg  
58  
59  
60

1  
2  
3  
4  
5  
6 suppositories may be used once to twice daily as a rescue medication when no bowel  
7  
8  
9 movement is observed for 72 or more consecutive hours, unless emergency use is  
10  
11  
12 required.  
13

14  
15 Because of potential effects on the study results and/or interpretation thereof, use of the  
16  
17 following drugs or therapies as concomitant medications will be prohibited: laxatives  
18  
19 other than elobixibat such as magnesium hydroxide, sodium picosulphate, sennosides,  
20  
21 lubiprostone, linaclotide, polyethylene glycol (macrogol 4000), etc.; oriental medicines  
22  
23 for constipation (daiokanzoto extract, choijokito extract, daisaikoto extract, etc.);  
24  
25 medicines indicated for irritable bowel syndrome (ramosetron hydrochloride,  
26  
27 polycarbophil calcium, trimebutine maleate, etc.); supplements or over-the-counter  
28  
29 drugs to improve the constipated condition; enema or intestinal lavage; lavage solution  
30  
31 for colonoscopy; drugs listed in the Precaution section of the package insert of  
32  
33 elobixibat (Goofice® 5 mg tablets) as “with caution for concomitant use” (bile acid  
34  
35 preparations such as ursodeoxycholic acid and chenodeoxycholic acid,  
36  
37  
38 aluminium-containing antacids such as sucralfate hydrate, aldioxa, etc., cholestyramine,  
39  
40  
41 cholestimid, digoxin, dabigatran etexylate methanesulfonate, and midazolam; other  
42  
43  
44 medicines or investigational drugs being used in clinical trials; non-internal therapy for  
45  
46  
47 constipation such as biofeedback therapy; disimpaction; and Duodopa® pump therapy.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Discontinuation of the study**

Participation of a recruited patient will be discontinued if any of the following conditions is met: judged difficult to continue due to the onset of an AE; ineligibility confirmed after study initiation; lost to follow-up; confirmed or suspected pregnancy; voluntary withdrawal; repeated protocol violations; or any other reason for which the (sub)investigator judges that discontinuation would be necessary.

All study procedures will be discontinued if any of the following conditions is met: the Institutional Review Board of Juntendo University Hospital determines that the study should be discontinued; the appearance of safety concerns with potential impact on study progress; appearance of incidents or information that may potentially lead to impairment of ethical or scientific validity of the study; or appearance of any other incidents or information that may potentially lead to impairment of appropriateness of study conduct and/or reliability of study results.

### **Observations and measurements**

Patient background, medical history and complications, and data of physical examinations will be collected at Visit 1 (Figure 2). On final judgment regarding study

1  
2  
3  
4  
5  
6 registration at Visit 2, subjective symptoms and objective findings, medical history and  
7  
8  
9 complications, physical examinations, and vital signs will be recorded for the eligible  
10  
11  
12 patients. Subjective symptoms and objective findings will be collected twice more at  
13  
14  
15 Visits 3 and 4. Physical examinations and vital signs will also be recorded at Visit 4.  
16  
17  
18 The JPAC-QOL,[18] MDS-UPDRS,[19] PDQ-39,[20] and EQ-5D-5L21,[22] surveys  
19  
20  
21 and laboratory measurements (haematology and blood chemistry) will be recorded at  
22  
23  
24 Visits 2 and 4 (Figure 2).  
25

26  
27 Each patient will receive a Bowel Movement Diary at Visit 1 and will then record daily  
28  
29  
30 the status of bowel movements (date, stool hardness based on the Bristol scale,[17] and  
31  
32  
33 sensation of incomplete evacuation), use of rescue medication (date, dose of bisacodyl  
34  
35  
36 suppositories) and concomitant medication (drugs for treatment of PD-related motor  
37  
38  
39 symptoms; date, drug name, dose), and treatment with non-investigational drugs and/or  
40  
41  
42 therapy for constipation. If the patient enters the treatment period, he/she will continue  
43  
44  
45 to record those items and also record daily use of the investigational drug (elobixibat or  
46  
47  
48 placebo; date and dose, i.e. number of tablets taken) in the Diary starting at Visit 2 up to  
49  
50  
51 the end of study (Visit 4). Discontinuation, if it occurs, should also be recorded in the  
52  
53  
54 Diary with its date and reason.  
55  
56  
57  
58  
59  
60

## Safety information

This study will specifically focus on AEs that are suspected to have occurred in association with study conduct and include any of study conduct-associated events, impairments, deaths, infections, laboratory abnormalities, and symptoms.

The (sub)investigator will examine the patient for AEs throughout the study period (Figure 2) and upon finding an event, record in the patient's eCRF its: name; onset date; severity (mild, moderate, or severe); seriousness (non-serious or serious); defined category of seriousness (death, life-threatening, hospitalization-initial or prolonged, disability or permanent damage, an event potentially leading to disability or permanent damage, ill condition judged as serious in reference to the aforementioned categories, or congenital anomaly or birth defect); predictability (known or unknown); action taken regarding the investigational drug (continuation, interruption, or discontinuation); outcome (recovered, improving, not recovered, recovered with sequelae, died, or unknown); date of outcome; causal relationship with use of the investigational drug ('not related' or grades other than 'not related'; suspected factor(s) other than the investigational drug should be recorded if judged 'not related').

## Study population and statistical analysis

1  
2  
3  
4  
5  
6 Based on the efficacy assessment of elobixibat vs. placebo in phase 2 and phase 3  
7  
8  
9 clinical trials conducted in Japanese patients with chronic constipation,[28-30] we  
10  
11  
12 estimated a sample size of 40 patients for each group for 90% detection power at a  
13  
14  
15 two-sided significance level of 5%. Assuming a dropout rate of 20%, we plan to recruit  
16  
17  
18 100 PD patients with chronic constipation in this study.

19  
20  
21 The full analysis set (FAS) is defined as the randomised population receiving at least  
22  
23  
24 one dose of the investigational drug with any measurement with regard to efficacy  
25  
26  
27 assessment. To ensure the robustness of study results, we also define a per-protocol set  
28  
29  
30 (PPS) as the population after the patients are excluded from the FAS due to any of the  
31  
32  
33 following reasons: any of the inclusion criteria inapplicable or any of the exclusion  
34  
35  
36 criteria applicable; a patient receiving the investigational drug with a non-allocated drug  
37  
38  
39 number; a patient receiving prohibited concomitant medications or therapies; a patient  
40  
41  
42 deemed to be inappropriate for study participation due to low drug compliance, lost to  
43  
44  
45 follow-up, lack of measurements, etc. The safety analysis set is defined as a population  
46  
47  
48 receiving at least one dose of the investigational drug after randomization.

49  
50  
51 Continuous variables and categorical variables will be presented as means±standard  
52  
53  
54 deviation (SD) and as frequencies and percentages, respectively. Summary statistics  
55  
56  
57 may include medians and quartiles, as appropriate. Comparisons will be made for  
58  
59  
60

1  
2  
3  
4  
5  
6 primary outcomes between the elobixibat group and the placebo group by analysis of  
7  
8  
9 covariance (ANCOVA) using baseline values and sex as covariates. Adjusted means  
10  
11  
12 with 95% confidence intervals and p values will be presented at a two-sided  
13  
14  
15 significance level of 5%. Within-group variations will be assessed by paired *t*-tests.  
16  
17  
18 Missing values will be imputed by the last observation carried forward (LOCF) method.  
19  
20  
21 Safety data will be shown as frequencies and percentages by group and individual event.  
22  
23  
24  
25  
26

## 27 **PATIENT AND PUBLIC INVOLVEMENT**

28  
29  
30 No formal patient advisory committee was established, and there was no patient or  
31  
32  
33 public involvement in the design and planning of the study.  
34  
35  
36  
37

## 38 **ETHICS AND DISSEMINATION**

39  
40  
41 This study will be conducted according to the protocol that has been prepared in  
42  
43  
44 accordance with the Helsinki Declaration, Clinical Trials Act of the Japan Ministry of  
45  
46  
47 Health, Labour and Welfare, and related laws and regulations. Each study patient will  
48  
49  
50 be anonymously identified by a specific identification code and hence protected against  
51  
52  
53 privacy invasion. The information and data of each patient will be used exclusively for  
54  
55  
56 the study purpose and will never be disseminated outside the study.  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 As a coordinating centre, SRD Co., Ltd. will share necessary information related to this  
7  
8  
9 study at the participating medical organizations in this study, conduct operations aimed  
10  
11  
12 at facilitating this study, and provide support to investigators.  
13  
14

15 Data management and monitoring are conducted by Juntendo Clinical Research and  
16  
17  
18 Trial Center, Juntendo University Hospital. Details are specified in the Data  
19  
20  
21 Management Plan and Monitoring Plan.  
22  
23

24 If a serious health hazard arises due to participation in this study, coverage benefits can  
25  
26  
27 be received from insurance carried by a principal investigator, provided, however, that  
28  
29  
30 compensation may be reduced or not compensated if it is proven that the health hazard  
31  
32  
33 was caused by the research subject's own wilful act or gross negligence. In addition, if  
34  
35  
36 there is no causal relationship between the newly occurring health hazard and the  
37  
38  
39 deterioration of the originally affected disease, it is not covered by compensation. After  
40  
41  
42 completion of the study by each research subject, the investigators will make efforts to  
43  
44  
45 provide the best medical care obtained from the results of the research.  
46  
47  
48  
49  
50

## 51 **DISCUSSION AND DISSEMINATION**

52  
53

54 PD treatment is usually focused on the amelioration of movement dysfunction.  
55  
56

57 However, patients with PD have many non-motor symptoms, especially autonomic  
58  
59  
60

1  
2  
3  
4  
5  
6 dysfunction. Chronic constipation has been considered one of the troublesome  
7  
8 symptoms affecting the QOL of PD patients, and it may even be life-threatening.  
9

10  
11 Although fermented milk products containing probiotics and prebiotic fibres may have a  
12  
13 favourable effect on PD-related constipation, they will not be available as laxatives.  
14  
15

16  
17 Although multiple classes of laxatives are available, there is little evidence supporting  
18  
19 their use for PD-related constipation. An evidence-based medicine review[1]  
20  
21 recommends only three drugs/foods for PD-related constipation, including macrogol,  
22  
23 lubiprostone, and probiotics/prebiotic fibres. Two laxatives are considered “likely  
24  
25 efficacious” and “possibly useful” for the treatment of constipation in PD patients based  
26  
27 on the quality of randomised, controlled trials. We believe the randomised, clinical  
28  
29 study proposed here will be useful for expanding treatment options for PD-related  
30  
31 constipation in an evidence-based manner.  
32  
33  
34  
35  
36  
37  
38  
39  
40

41  
42 The study findings will be presented at relevant conferences and published in a  
43  
44 peer-reviewed journal.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**REFERENCES**

1. Seppi K, Chaudhuri KR, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. *Mov Disord* 2019;34:180-98. <https://doi.org/10.1002/mds.27602>.
2. Fasano A, Visanji NP, Liu LWC, et al. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol* 2015;14:625-39. [https://doi.org/10.1016/S1474-4422\(15\)00007-1](https://doi.org/10.1016/S1474-4422(15)00007-1).
3. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol* 2003;2:107–16. [https://doi.org/10.1016/s1474-4422\(03\)00307-7](https://doi.org/10.1016/s1474-4422(03)00307-7).
4. Yu Q-J, Yu S-Y, Zuo L-J, et al. Parkinson disease with constipation: clinical features and relevant factors. *Scient Rep* 2018;8:567-75. <https://doi.org/10.1038/s41598-017-16790-8>.
5. Stirpe P, Hoffman M, Badiali D, et al. Constipation: an emerging risk factor for Parkinson's disease? *Eur J Neurol* 2016;23:1606–13.

1  
2  
3  
4  
5  
6 <https://doi.org/10.1111/ene.13082>.

- 7  
8  
9  
10  
11  
12 6. Mishima T, Fukae J, Fujioka S, et al. The prevalence of constipation and irritable  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
6. Mishima T, Fukae J, Fujioka S, et al. The prevalence of constipation and irritable  
bowel syndrome in Parkinson's disease patients according to Rome III diagnostic  
criteria. *J Parkinson's Dis* 2017;7:353-7. <https://doi.org/10.3233/JPD-160982>.
7. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-  
based medicine review update: treatment for the non-motor symptoms of  
Parkinson's disease. *Mov Disord* 2011;26:S42-80.  
<https://doi.org/10.1002/mds.23884>.
8. Rossi M, Merello M, Perez-Lloret S. Management of constipation in Parkinson's  
disease. *Expert Opin Pharmacother* 2015;16: 547-57.  
<https://doi.org/10.1517/14656566.2015.997211>.
9. Clinical Practice Guidelines for Chronic Constipation 2017 ed. by Study Group of  
the diagnosis and treatment of chronic constipation: The Japanese Society of  
Gastroenterology (*in Japanese*) Nankodo Co., Ltd., Tokyo Japan.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10 10. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of  
11  
12 constipation in Parkinson's disease. A randomized placebo-controlled study. *Mov*  
13  
14 *Disord* 2007;22:1239-44. <https://doi.org/10.1002/mds.21243>.  
15  
16  
17  
18  
19  
20  
21 11. Ondo WG, Kenny C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for  
22  
23 constipation associated with Parkinson disease. *Neurology* 2012;78:1650-4.  
24  
25 <https://doi.org/10.1212/WNL.0b013e3182574f28>.  
26  
27  
28  
29  
30  
31  
32  
33 12. Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for  
34  
35 constipation associated with Parkinson disease: an RCT. *Neurology*  
36  
37 2016;87:1274-80. <https://doi.org/10.1212/WNL.00000000000003127>.  
38  
39  
40  
41  
42  
43  
44  
45 13. Cassani E, Privitera G, Pezzoli G, et al. Use of probiotics for the treatment of  
46  
47 constipation in Parkinson's disease patients. *Minerva Gastroenterol Dietol*  
48  
49 2011;57:117-21.  
50  
51  
52  
53  
54  
55  
56  
57 14. Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic  
58  
59  
60

1  
2  
3  
4  
5  
6 constipation. *Therap Adv Gastroenterol* 2014;7:167-75.

7  
8  
9 <https://doi.org/10.1177/1756283X14528269>.

10  
11  
12  
13  
14  
15 15. Wingate DL, Krag E, Mekhjian HS, et al. Relationships between ion and water  
16  
17 movement in the human jejunum, ileum and colon during perfusion with bile acids.  
18  
19  
20  
21 *Clin Sci Mol Med* 1973;45:593-606. <https://doi.org/10.1042/cs0450593>.

22  
23  
24  
25  
26  
27 16. Bampton PA, Dinning PG, Kennedy ML, et al. The proximal colonic motor  
28  
29 response to rectal mechanical and chemical stimulation. *Am J Physiol Gastrointest*  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
*Liver Physiol* 2002;282:G443-9. <https://doi.org/10.1152/ajpgi.00194.2001>.

17. Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool  
form in the general population: a prospective study. *Gut* 1992;33:818-24.  
<https://doi.org/10.1136/gut.33.6.818>.

18. Nomura H, Agatsuma T, Mimura T. Validity and reliability of the Japanese version  
of the patient assessment of constipation quality of life questionnaire. *J*  
*Gastroenterol* 2014;49:667-73. <https://doi.org/10.1007/s00535-013-0825-y>.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
19. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Movement Disord* 2008;23:2129-70. <https://doi.org/10.1002/mds.22340>.
20. Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. *Qual Life Res* 1995;4:241-8. <https://doi.org/10.1007/BF02260863>.
21. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727-36. <https://doi.org/10.1007/s11136-011-9903-x>.
22. Young MK, Ng S-K, Mellick G, et al. Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease. *Qual Life Res* 2013;22:1065-72. <https://doi.org/10.1007/s11136-012-0231-6>.
23. Postuma RB, Berg D, Stem M, et al. MDS clinical diagnostic criteria for

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Parkinson's disease. *Mov Disord* 2015;30:1591-601.

<https://doi.org/10.1002/mds.26424>.

24. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. *Mov Disord* 2004;19:1020-8. <https://doi.org/10.1002/mds.20213>.

25. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. *Gastroenterol* 2016;150:1257-61. <https://doi.org/10.1053/j.gastro.2016.03.035>.

26. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. *Gastroenterol* 2016;150:1262-79. <https://doi.org/10.1053/j.gastro.2016.02.032>.

27. Pangman VC, Sloan J, Guse, L. An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice. *Appl Nurs Res* 2000;13:209-13.



1  
2  
3  
4  
5  
6 <https://doi.org/10.1053/apnr.2000.9231>.  
7  
8  
9  
10

- 11  
12 28. Nakajima A., Seki M., Taniguchi S. Determining an optimal clinical dose of  
13  
14 elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients  
15  
16 with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled  
17  
18 randomized clinical trial. *J Gastroenterol* 2018;53:525-34.  
19  
20  
21

22 <https://doi.org/10.1007/s00535-017-1383-5>.  
23  
24  
25  
26  
27  
28  
29

- 30 29. Nakajima A, Seki M, Taniguchi S, et al. Safety and efficacy of elobixibat for  
31  
32 chronic constipation: results from a randomised, double-blind, placebo-controlled,  
33  
34 phase 3 trial and an open-label, single-arm, phase 3 trial. *Lancet Gastroenterol*  
35  
36  
37  
38  
39 *Hepatol* 2018;3:537-47. [https://doi.org/10.1016/S2468-1253\(18\)30123-7](https://doi.org/10.1016/S2468-1253(18)30123-7).  
40  
41  
42  
43  
44

- 45 30. Common Technical Document section 1.5 for Goofice 5 mg tablets by EA Pharma  
46  
47  
48 Co., Ltd. (*in Japanese*)  
49

50  
51 <https://www.pmda.go.jp/drugs/2018/P20180201001/index.html>  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgements

The authors would like to thank Forte Science Communications (Tokyo, Japan) for professional assistance in preparing this manuscript.

## Authors' Contributions

TH, GO, and NH were involved in conception and trial design. TH was involved in drafting of the article. TH, GO, YS, KO, NN, JF, RN, NK, TT, YO, SS, KN, HE, AF, AN, MK, DT, TO, HTA, HK, SN, and NH were involved in critical revision of the article for important intellectual content. All the authors were involved in final approval of the article. NY provided statistical expertise.

## Data availability statement

Data are available on reasonable request (TH; thatano@juntendo.ac.jp).

## Funding

This study will be funded by EA Pharma Co., Ltd. (Tokyo) and Mochida Pharmaceutical Co., Ltd. (Tokyo) (grant number: N/A). The two companies also provide clinical supplies, the Bowel Movement Diary, and other products necessary for

1  
2  
3  
4  
5  
6 study conduct. It should be noted that the two companies and their employees will never  
7  
8  
9 be involved in any study procedures including collection, analysis or interpretation of  
10  
11  
12 data, ensuring (sub)investigators will be completely independent of the funders  
13  
14  
15 throughout study conduct.  
16  
17  
18  
19  
20

### 21 **Competing interests**

22  
23  
24 There are no competing interests.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## FIGURE LEGENDS

### Figure 1 Study outline

Washout: previous medications except for anti-Parkinsonian medications will be washed out during the observation period.

Consent: written, informed consent

Exam.: physical examinations

Test: laboratory tests

Eligibility: eligibility confirmed for study participation

Alloc.: patient allocation to either treatment with elobixibat or with placebo

Prescrip.: prescription of the investigational medication according to patient allocation

Drug retrieval: unused/remaining investigational medications will be retrieved.

### Figure 2 Study schedule

<sup>a</sup>: Allowance denotes the time window allowed relative to the date of Visit 1 for Visit 2 and Visit 2 for Visits 3 and 4.

<sup>b</sup>: Temporary registration for study participation

<sup>c</sup>: Final registration for study participation

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1




Figure 1 Study outline

253x190mm (300 x 300 DPI)

Figure 2

		Observation period	Administration start	Treatment period	
Visit		Visit 1	Visit 2	Visit 3	Visit 4
Date (Allowance <sup>a</sup> )		14 days prior to Visit 2	Day 1 (≤ 5 days post-Visit 2)	Day 15 post Visit 2 (± 7 days)	Day 29 post Visit 2 (≤ 7 days) or discontinuation
Informed consent		○			
Eligibility confirmation		○ (Temp. regist. <sup>b</sup> )	○ (Final regist. <sup>c</sup> )		
	Patient background	○			
	Subjective symptoms/objective findings		○	○	○
Physical examinations	History/complications	○	○		
	Physical examinations	○	○		○
	Vital signs (blood pressure/pulse rate)		○		○
	Use of investigational medication		←	→	→
Bowel Movement Diary	Use of rescue/concomitant medication	←	→	→	→
	Bowel movement	←	→	→	→
	Other therapy for constipation	←	→	→	→
Adverse events	←	→	→	→	→
	JPAC-QOL		○		○
	MDS-UPDRS		○		○
	PDQ-39		○		○
	EQ-5D		○		○
Laboratory tests	Haematology		○		○
	Blood chemistry		○		○

Figure 2 Study schedule

253x190mm (300 x 300 DPI)



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 4 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ 4 ___
Protocol version	3	Date and version identifier	___ 10 ___
Funding	4	Sources and types of financial, material, and other support	___ 34 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 34 ___
	5b	Name and contact information for the trial sponsor	___ 34 ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ 6-8 ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ 22 ___

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention \_\_6-8\_\_

4

5

6 6b Explanation for choice of comparators \_\_NA\_\_

7

8 Objectives 7 Specific objectives or hypotheses \_\_6-8\_\_

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) \_\_6-8, 10, 11\_\_

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained \_\_10\_\_

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) \_\_11, 13\_\_

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered \_\_10, 11\_\_

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) \_\_15-17\_\_

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) \_\_13-15\_\_

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial \_\_13-17\_\_

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended \_\_17, 18\_\_

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) \_\_Fig. 2\_\_

41

42

43

44

45

46



1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including \_\_\_19-21\_\_\_  
 2 clinical and statistical assumptions supporting any sample size calculations

3  
 4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size \_\_\_19-21\_\_\_  
 5

6 **Methods: Assignment of interventions (for controlled trials)**

7  
 8 Allocation:

9  
 10 Sequence 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any \_\_\_13-15\_\_\_  
 11 generation factors for stratification. To reduce predictability of a random sequence, details of any planned restriction  
 12 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants  
 13 or assign interventions  
 14  
 15

16 Allocation 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, \_\_\_13-15\_\_\_  
 17 concealment opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned  
 18 mechanism  
 19

20 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to \_\_\_13-15\_\_\_  
 21 interventions  
 22

23 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome \_\_\_13-15\_\_\_  
 24 assessors, data analysts), and how  
 25  
 26 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's \_\_\_13-15\_\_\_  
 27 allocated intervention during the trial  
 28  
 29  
 30

31 **Methods: Data collection, management, and analysis**

32  
 33 Data collection 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related \_\_\_19-21\_\_\_  
 34 methods processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of  
 35 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.  
 36 Reference to where data collection forms can be found, if not in the protocol  
 37

38  
 39 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be \_\_\_19-21\_\_\_  
 40 collected for participants who discontinue or deviate from intervention protocols  
 41  
 42

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___22___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___8, 9, 19-21___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___8, 9___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___19-21___
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___22___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___17___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___10-13___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___34, 35___
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___21, 22___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___10-13___
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	___ 15 ___
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	___ NA ___
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	___ 17, 21, 22 ___
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	___ 34, 35 ___
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	___ 34 ___
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	___ 22 ___
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	___ 26 ___
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	___ 34 ___
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	___ NA ___
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	___ NA ___
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	___ NA ___
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.  
 40

# BMJ Open

**Protocol: A multicentre, placebo-controlled, randomised, double-blind, parallel-group study investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation (CONST-PD)**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054129.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Oct-2021
Complete List of Authors:	Hatano, Taku; Juntendo University, Neurology Oyama, Genko; Juntendo University Faculty of Medicine, Department of Neurology; Juntendo University Faculty of Medicine Shimo, Yasushi; Juntendo University School of Medicine, Department of Neurology Ogaki, Kotaro ; Juntendo Urayasu Hospital Nishikawa, Noriko ; Juntendo University Faculty of Medicine Fukae, Jiro ; Juntendo Nerima Hospital Nakamura, Ryota ; Juntendo Urayasu Hospital Kurita, Naohide ; Juntendo Urayasu Hospital Tsunemi , Taiji ; Juntendo University Faculty of Medicine Oji, Yutaka ; Juntendo University Faculty of Medicine Saiki, Shinji ; Juntendo University Faculty of Medicine Nishioka, Kenya ; Juntendo University Faculty of Medicine Takeshige, Haruka; Juntendo University Faculty of Medicine Taniguchi, Daisuke ; Juntendo University Faculty of Medicine Ogawa, Takashi; Juntendo University School of Medicine, Neurology Kamo, Hikaru ; Juntendo University Faculty of Medicine Eguchi, Hiroto ; Juntendo Nerima Hospital Fuse, Atsuhito ; Juntendo Nerima Hospital Nakajima, Asuka ; Juntendo Nerima Hospital Kano, Masayoshi ; Juntendo Nerima Hospital Nakajima, Sho ; Juntendo Urayasu Hospital Yanagisawa, Naotake; Juntendo University Hospital Hattori, Nobutaka ; Juntendo University Graduate School of Medicine, Neurology
<b>Primary Subject Heading</b>:	Neurology
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	Parkinson-s disease < NEUROLOGY, Motility disorders < GASTROENTEROLOGY, Clinical trials < THERAPEUTICS

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 **Protocol: A multicentre, placebo-controlled, randomised, double-blind,**  
7  
8  
9 **parallel-group study investigating the efficacy and safety of elobixibat, an ileal bile**  
10  
11 **acid transporter inhibitor, in patients with Parkinson's disease with chronic**  
12 **constipation (CONST-PD)**  
13  
14  
15  
16

17  
18  
19  
20  
21 Taku Hatano<sup>1</sup>, Genko Oyama<sup>1</sup>, Yasushi Shimo<sup>2</sup>, Kotaro Ogaki<sup>3</sup>, Noriko Nishikawa<sup>1</sup>,  
22  
23 Jiro Fukae<sup>2</sup>, Ryota Nakamura<sup>3</sup>, Naohide Kurita<sup>3</sup>, Taiji Tsunemi<sup>1</sup>, Yutaka Oji<sup>1</sup>, Shinji  
24  
25 Saiki<sup>1</sup>, Kenya Nishioka<sup>1</sup>, Haruka Takeshige-Amano<sup>1</sup>, Daisuke Taniguchi<sup>1</sup>, Takashi  
26  
27 Ogawa<sup>1</sup>, Hikaru Kamo<sup>1</sup>, Hiroto Eguchi<sup>2</sup>, Atsuhito Fuse<sup>2</sup>, Asuka Nakajima<sup>2</sup>, Masayoshi  
28  
29 Kano<sup>2</sup>, Sho Nakajima<sup>3</sup>, Naotake Yanagisawa<sup>4</sup>, Nobutaka Hattori<sup>1</sup>  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<sup>1</sup> Department of Neurology, Juntendo University Faculty of Medicine, 2-1-1 Hongo,  
Bunkyo-ku, Tokyo 113-8421, Japan

<sup>2</sup> Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai,  
Nerima-ku, Tokyo 177-8521, Japan

<sup>3</sup> Department of Neurology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka,  
Urayasu, Chiba 279-0021, Japan

<sup>4</sup> Juntendo Clinical Research and Trial Center, Juntendo University Hospital, 3-1-1,

1  
2  
3  
4  
5  
6 Hongo, Bunkyo-ku, Tokyo, Japan  
7  
8  
9  
10

11  
12 Correspondence to: Taku Hatano; thatano@juntendo.ac.jp and Nobutaka Hattori;  
13

14  
15 nhattori@juntendo.ac.jp  
16  
17

18  
19  
20  
21 **Word count:** 3920  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## ABSTRACT

### Introduction

Chronic constipation can worsen the quality of life (QOL) of Parkinson's disease (PD) patients. Elobixibat, an ileal bile acid transporter inhibitor, is known to be a useful laxative, but its effect on chronic constipation in PD patients remains unclear. Therefore, we have planned a placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of elobixibat in PD patients with chronic constipation.

### Methods and analysis

The study will consist of 2-week observation and 4-week treatment periods. Patients diagnosed with clinically established PD will record the status of spontaneous bowel movements and use of rescue medications/concomitant medications in a Bowel Movement Diary from the start of the observation period at Visit 1 (Week -2). At Visit 2 (Week 0), patients will be assessed for final registration based on the Diary records and physical examinations, and allocated to either the elobixibat or placebo group. Daily intake of the investigational drug will be recorded in the Diary. Patients will undergo laboratory tests and answer constipation-related, PD-related, and QOL-related questionnaires at Visit 2 and Visit 4 (Week 4). Subjective symptoms and objective findings will be collected at Visits 2, 3 (Week 2), and 4. Since patients' motor function might be improved by treatment of constipation, the use of dopamine preparations will also be monitored. Bowel movement data and other parameters will be compared between the groups.

Safety information will be collected as adverse events, specifically focusing on those occurring in association with study conduct.



## **Ethics and dissemination**

This study will be conducted in accordance with the Helsinki Declaration, the Clinical Trials Act of the Japan Ministry of Health, Labour and Welfare, and related laws and regulations. Patient data will be anonymized to protect privacy and used only for the study purpose. The present study was approved by the Juntendo University Certified Review Board.

**Registration number of this study:** JPRN-jRCTs031200172 (Japan Primary Registries Network)

## **Keywords**

Parkinson's disease, Motility disorders, Clinical trials

### Strengths and limitations of the study

- Given that there is evidence that probiotic/prebiotic fibre, lubiprostone, and macrogol improve chronic constipation in Parkinson's disease (PD) patients, this study is expected to provide further evidence to expand treatment options in PD patients, using a different anti-constipation drug with a different mode of action.
- Elobixibat, an ileal bile acid transporter inhibitor and a new class of laxative, may improve constipation and, thereby, quality of life in PD patients.
- Because of the short study period (4-week administration), the long-term efficacy and safety of elobixibat may not be clarified.
- Bowel Movement Diary data might have limited credibility because they are based on the patients' subjective responses.

## INTRODUCTION

Parkinson's disease (PD) is one of the most common neurodegenerative disorders.

Whereas PD is commonly considered a movement disorder, patients with PD have many difficulties with non-motor symptoms, such as dementia, anxiety, sleep disturbance, and autonomic dysfunction.[1] Chronic constipation is one of the common digestive complications experienced by PD patients even before or at an early stage of disease progression, with its frequency varying from 7% to 70% depending on the definition.[2-6] Since long-lasting constipation may decrease quality of life (QOL) and be occasionally accompanied by life-threatening intestinal perforation and/or megacolon syndrome, it should be appropriately controlled.[7,8]

Multiple types of laxatives are conventionally available for the treatment of chronic constipation, including bulk-forming agents such as carmellose sodium and dioctyl sodium sulfosuccinate, stimulants such as sennoside and sodium picosulphate hydrate, and osmotic agents such as cathartic salts (magnesium oxide and magnesium sulphate).

While stimulants and cathartic salts have been widely used, stimulants may cause intractable constipation via drug resistance if used consecutively for a long duration, and magnesium oxide may cause hypermagnesemia in elderly patients and patients with kidney malfunction.[9]

1  
2  
3  
4  
5  
6 Recently, in addition to existing osmotic agents (macrogol 4000 often in combination  
7  
8  
9 with electrolytes, movicol, lactulose), new classes of laxatives have been developed for  
10  
11  
12 chronic constipation, including epithelial function transformation drugs (lubiprostone,  
13  
14  
15 linaclotide) and an ileal bile acid transporter (IBAT) inhibitor (elobixibat).  
16

17  
18 However, the evidence for the effectiveness of laxatives either conventional or recently  
19  
20  
21 developed for the treatment of chronic constipation in PD patients is not extensive,  
22  
23  
24 except for macrogol and lubiprostone, a chloride channel-2 activator, which have been  
25  
26  
27 shown to be significantly efficacious over placebo in improving bowel movement  
28  
29  
30 frequency.[10, 11] Although probiotics and prebiotic fibre were also proposed to be  
31  
32  
33 useful for the treatment of PD-related constipation,[12, 13] more evidence for different  
34  
35  
36 classes of laxatives is needed to expand therapeutic options for chronic constipation in  
37  
38  
39 PD patients.  
40

41  
42 Elobixibat is an inhibitor of IBAT, which is expressed in the distal ileum. Bile acids  
43  
44  
45 escape the reabsorption process via the action of this drug and then enter the large  
46  
47  
48 intestinal lumen.[14] The increased levels of bile acids may interact with  
49  
50  
51 transmembrane G-protein-coupled receptor (TGR5) molecules, leading to an influx of  
52  
53  
54 water and electrolytes into the lumen. The bile acid-TGR5 interaction also triggers  
55  
56  
57 serotonin release into the intestinal wall, which activates intrinsic primary afferent  
58  
59  
60

1  
2  
3  
4  
5  
6 neurons. This leads to an interneuron-mediated activation of motor neurons that finally  
7  
8  
9 activates large-intestinal motility,[15] inducing colonic high-amplitude propagated  
10  
11  
12 contractions.[16] Recently, a large-scale, multicenter, randomized, double-blind phase 3  
13  
14  
15 study was conducted, revealing that elobixibat resolved idiopathic chronic constipation  
16  
17  
18 with no serious safety concerns.[17] Elobixibat is thus expected to be a novel option for  
19  
20  
21 the treatment of chronic constipation on the basis of its mode of action being totally  
22  
23  
24 different from those of the other existing laxatives.[18, 19]

25  
26  
27 We are planning to conduct a study to examine the efficacy and safety of elobixibat in  
28  
29  
30 PD patients with chronic constipation. The superiority of elobixibat over placebo will be  
31  
32  
33 explored in a randomized, double-blind, comparative study during 4-week daily  
34  
35  
36 administration of the drug to eligible patients. The drug will also be evaluated for its  
37  
38  
39 safety and potential impact on the underlying PD condition. The study methodology is  
40  
41  
42 detailed in this article.  
43  
44  
45  
46

## 47 **METHODS AND ANALYSIS**

48  
49  
50 The objective of this study is to explore a novel therapeutic option for chronic  
51  
52  
53 constipation in PD patients. The conduct of the present study was approved by the  
54  
55  
56 Juntendo University Certified Review Board.  
57  
58  
59  
60

### Primary endpoints

The weekly frequency of spontaneous bowel movements with no assistance from rescue therapies such as bisacodyl suppositories, enema, disimpaction, etc. (see below) will be recorded during each 7-day segment of the treatment period (Week 0-1 up to Week 3-4; see Figure 1). Bowel movements observed within 24 hours of suppository use will not be counted. Changes in the frequency at Visit 4 (Week 4) from baseline (Visit 2/Week 0; see Figure 1) will be compared between the elobixibat group and the placebo group.

### Secondary endpoints

Weekly changes from baseline in the frequency of spontaneous bowel movements and complete spontaneous bowel movements (i.e., no sensation of incomplete evacuation) will be assessed throughout the treatment period (Visit 4/Week 4; Figure 1). Changes from baseline in stool form will also be assessed up to Week 4 using the Bristol Scale.[20]

Use of rescue medication and questionnaire surveys using the Japanese version of Patient Assessment of Constipation Quality of Life (JPAC-QOL),[21] Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS),[22]

1  
2  
3  
4  
5  
6 Parkinson's Disease Questionnaire-39 (PDQ-39),[23] and Euro-Qol 5 dimension – 5  
7  
8  
9 level (EQ-5D-5L)[24,25] will be assessed. The use of dopamine preparations will also  
10  
11  
12 be monitored, since the effectiveness of elobixibat in improving constipation via  
13  
14  
15 increased levels of intestinal bile acids may also improve small intestinal absorption of  
16  
17  
18 the anti-Parkinsonian medications.  
19

20  
21 Subgroup analyses will be further performed for these endpoints by the presence or  
22  
23  
24 absence of complications, age ( $\geq$  or  $<$ 65 years), Hoehn and Yahr scale (1 to 4), duration  
25  
26  
27 of the underlying disease (PD;  $\geq$  or  $<$ median), dose equivalence of L-Dopa prior to  
28  
29  
30 elobixibat initiation, and duration of chronic constipation ( $\geq$  or  $<$ 20 years).  
31  
32  
33  
34  
35

### 36 **Overall study design**

37  
38  
39 This study is designed as a multicentre, randomised, double-blind, placebo-controlled,  
40  
41  
42 parallel-group study at 3 academic centres (Juntendo University Hospital, Juntendo  
43  
44  
45 University Urayasu Hospital, and Juntendo University Nerima Hospital), in which PD  
46  
47  
48 patients with chronic constipation will pre-prandially receive elobixibat (Goofice®; EA  
49  
50  
51 Pharma Co., Ltd., Tokyo, Japan) or its indistinguishable matched placebo once daily for  
52  
53  
54 four weeks, and the frequency of spontaneous bowel movements will be compared  
55  
56  
57 between the patients receiving either elobixibat or placebo. Safety information,  
58  
59  
60

1  
2  
3  
4  
5  
6 including adverse events (AEs) and discontinuation and interruption of the  
7  
8  
9 investigational drugs, will also be collected.  
10

11  
12 The study will consist of two periods, the observation period and the treatment period. It  
13  
14 will be conducted from October 26, 2020 (date of the first announcement in the Japan  
15  
16 Registry of Clinical Trials; jRCT) through September 30, 2022. As seen in Figure 1, we  
17  
18 plan two steps for patient registration, temporary and final. At Week -2 (Visit 1) of the  
19  
20 observation period, PD patients will be provided with the detailed information about the  
21  
22 study. After providing written, informed consent for study participation, they will be  
23  
24 temporarily registered based on the patient definitions (see below). Following the  
25  
26 observation period, the patients will be further assessed for study participation at Week  
27  
28 0 (Visit 2). Once none of the exclusion criteria are confirmed to be applicable, the  
29  
30 patients will be finally registered and assigned to either the elobixibat group or the  
31  
32 placebo group in a double-blind manner (Figure 1). The eligible patients will visit their  
33  
34 clinical sites twice more (Visit 3 at Week 2 and Visit 4 at Week 4) during the 4-week  
35  
36 treatment period.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 A Bowel Movement Diary will be provided at Week -2 (Visit 1, see below) to each  
52  
53 patient, once temporarily registered. The patient will record drug use, bowel movements,  
54  
55 etc. in the Diary daily throughout the study period.  
56  
57  
58  
59  
60



## Patient definitions

Patients will be diagnosed as having PD in reference to the diagnostic criteria defined by the International Parkinson and Movement Disorder Society (MDS)[26] and must be in stages 1 to 4 on the Hoehn and Yahr scale.[27] The diagnosis of chronic constipation will be made referring to the Rome IV-defined criteria.[28,29] Outpatients aged  $\geq 20$  years at the time of informed consent must have two or more of the following symptoms related to spontaneous bowel movements from at least 6 months before consent: i)  $< 3$  spontaneous bowel movements per week; ii) straining frequency  $> 25\%$  of defecations; iii) frequency of lumpy or hard stools  $> 25\%$  of defecations; and iv) sensation of incomplete evacuation  $> 25\%$  of defecations. Patients who meet these criteria will be temporarily registered, once written, informed consent is provided (Figure 1).

A PD patient will be excluded at temporary registration if he/she: has (or is suspected to have) organic constipation or dyschezia; is unable to use a rescue medication (bisacodyl 10 mg suppositories; Teleminsoft Suppositories<sup>®</sup> 10 mg, Cox Japan, Tokyo, Japan); currently has serious kidney dysfunction (creatinine  $\geq 2.00$  mg/dL), serious hepatic dysfunction (total bilirubin  $\geq 3.0$  mg/dL, or AST or ALT  $\geq 100$  U/L), or serious cardiac

1  
2  
3  
4  
5  
6 dysfunction; has malignant tumour(s); has a history of hypersensitivity to elobixibat; is  
7  
8  
9 taking bile acid preparations (ursodeoxycholic acid, chenodeoxycholic acid),  
10  
11  
12 aluminium-containing preparations (sucralfate hydrate, aldioxa, etc.), cholestyramine,  
13  
14  
15 colestimide, digoxin, dabigatran etexilate mesylate, or midazolam; has a Mini–Mental  
16  
17  
18 State Examination (MMSE) score<sup>[30]</sup>  $\leq 26$ ; or is considered ineligible by the  
19  
20  
21 investigator or sub-investigator, hereinafter termed (sub)investigator, for study  
22  
23  
24 participation because of safety concerns, poor protocol compliance, etc. Female patients  
25  
26  
27 will also be excluded if they are pregnant, breastfeeding, or expecting pregnancy during  
28  
29  
30 the study period.

31  
32  
33 Patient exclusion is further scheduled at the final registration if one of the following  
34  
35  
36 cases applies to a patient during the 2-week observation period: use of the rescue  
37  
38  
39 medication (bisacodyl 10 mg suppositories)  $\geq 5$  times; use of the rescue medication  
40  
41  
42 within 72 hours post-bowel movement; experience of spontaneous bowel movement  
43  
44  
45 with mushy or watery stool according to Bristol Stool Form Scale type 6 or 7;<sup>[20]</sup> or  
46  
47  
48 use of prohibited medications/therapies (see below).

### 54 **Study procedures and schedule**

55  
56  
57 Registration of study patients and their allocation to the investigational drug will be  
58  
59  
60

1  
2  
3  
4  
5  
6 performed via an internet-mediated Interactive Web Response System (IWRS). The  
7  
8  
9 (sub)investigator (or study-assigned coordinator) will access the specific website for  
10  
11  
12 patient registration and allocation using a specific ID and password, and complete the  
13  
14  
15 necessary information about each anonymized patient. Investigational drug allocation  
16  
17  
18 will be instantly presented for each patient following eligibility judgment (see below).  
19

20  
21 The schedule of this study is shown in Figure 2.  
22

23  
24 The (sub)investigator will give detailed explanations of this study to each PD patient  
25  
26  
27 who meets the inclusion criteria but not the exclusion criteria at Visit 1 and then obtain  
28  
29  
30 the patient's written, informed consent on a free will basis. The patient will be informed  
31  
32  
33 that he/she may withdraw his/her consent for any reason and at any time during the  
34  
35  
36 study period. The (sub)investigator will give the eligible patient a temporary  
37  
38  
39 identification code and enter the patient's background in the Eligibility for Temporary  
40  
41  
42 Registration form of the electronic Case Report Form (eCRF; see Figures 1 and 2).  
43  
44

45 The Bowel Movement Diary and rescue medication (bisacodyl 10 mg suppositories)  
46  
47  
48 will be provided to each patient at temporary registration. The (sub)investigator will  
49  
50  
51 instruct each patient how to complete the required items in the Diary.  
52

53  
54 At Visit 2, the (sub)investigator will judge the eligibility of each patient for final  
55  
56  
57 registration referring to the exclusion criteria (see above) and enter the background of  
58  
59  
60

1  
2  
3  
4  
5  
6 qualified patients in the Eligibility for Final Registration form of the eCRF. Once the  
7  
8  
9 patient's eligibility is confirmed, a final identification code will be assigned to the  
10  
11  
12 patient, who will be then allocated randomly to treatment group.

13  
14  
15 Drug allocation will be based on a stratified, permuted block method with sex as an  
16  
17 allocation factor. Satt Co., Ltd. (Tokyo) will perform the allocation by preparing a drug  
18  
19 allocation table using IWRS. The study drugs will be sealed with specific drug numbers  
20  
21 and delivered to the individual institutional sites according to the allocation table. At the  
22  
23 final registration of patients, the (sub)investigator will check the final identification  
24  
25 code and the specific number of randomly allocated investigational drug for each  
26  
27 qualified patient on the IWRS screen. The specifically numbered drug will be provided  
28  
29 to the patient by the (sub)investigator at Visit 2 and Visit 3 for 2 weeks each time (3  
30  
31 tablets x 14 days), as described below. The key code of the allocation table will be  
32  
33 opened by Satt after all study data has been locked.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 The patient will start the 4-week treatment period with once-daily, preprandial intake of  
46  
47 2 tablets of investigational drug (elobixibat 10 mg) or its placebo. One tablet may be  
48  
49 added on the next day if no spontaneous bowel movement is observed during the next  
50  
51 24 hours. If excessive effectiveness or discomfort appears, the dosage may be decreased  
52  
53  
54  
55  
56  
57 at the direction of the (sub)investigator or the patient's judgment. Dose augmentation  
58  
59  
60

1  
2  
3  
4  
5  
6 from 1 tablet to 3 tablets will not be allowed. Interruption of the investigational drug  
7  
8  
9 due to the occurrence of an AE may be allowed at the direction of the (sub)investigator  
10  
11  
12 or the patient's judgment, but as-needed intake of the drug based on bowel movement  
13  
14  
15 status will not be acceptable. The drug may be restarted at the dose taken immediately  
16  
17  
18 before interruption or at a lower dose. Inappropriately long ( $\geq 7$  consecutive days) or  
19  
20  
21 frequent ( $\geq 3$  days per week during 2 consecutive weeks) interruption of the drug may  
22  
23  
24 lead to discontinuation of the patient from the study at the (sub)investigator's discretion.  
25  
26  
27  
28  
29

### 30 **Rescue and concomitant medications/therapies**

31  
32  
33 Since this study is primarily planned to explore the efficacy and safety of elobixibat as a  
34  
35  
36 laxative in PD patients, concomitant medications will be used throughout the study  
37  
38  
39 period for parkinsonism except for Duodopa<sup>®</sup> pump therapy (Abbvie Inc., North  
40  
41  
42 Chicago, IL, USA) with levodopa/carbidopa hydrate intestinal gel. Bisacodyl 10 mg  
43  
44  
45 suppositories may be used once to twice daily as a rescue medication when no bowel  
46  
47  
48 movement is observed for 72 or more consecutive hours, unless emergency use is  
49  
50  
51 required.  
52  
53

54 Because of potential effects on the study results and/or interpretation thereof, use of the  
55  
56  
57 following drugs or therapies as concomitant medications will be prohibited throughout  
58  
59  
60

1  
2  
3  
4  
5  
6 the entire study period: laxatives other than elobixibat such as magnesium hydroxide,  
7  
8  
9 sodium picosulphate, sennosides, lubiprostone, linaclotide, polyethylene glycol  
10  
11  
12 (macrogol 4000), etc.; oriental medicines for constipation (daiokanzoto extract,  
13  
14  
15 choijokito extract, daisaikoto extract, etc.); medicines indicated for irritable bowel  
16  
17  
18 syndrome (IBS; ramosetron hydrochloride, polycarbophil calcium, trimebutine maleate,  
19  
20  
21 etc.); supplements or over-the-counter drugs to improve the constipated condition;  
22  
23  
24 enema or intestinal lavage; lavage solution for colonoscopy; drugs listed in the  
25  
26  
27 Precaution section of the package insert of elobixibat (Goofice® 5 mg tablets) as “with  
28  
29  
30 caution for concomitant use” (bile acid preparations such as ursodeoxycholic acid and  
31  
32  
33 chenodeoxycholic acid, aluminium-containing antacids such as sucralfate hydrate,  
34  
35  
36 aldioxa, etc., cholestyramine, cholestimid, digoxin, dabigatran etexylate  
37  
38  
39 methanesulfonate, and midazolam; other medicines or investigational drugs being used  
40  
41  
42 in clinical trials; non-internal therapy for constipation such as biofeedback therapy;  
43  
44  
45 disimpaction; and Duodopa® pump therapy. The patient should self-report in his/her  
46  
47  
48 Bowel Movement Diary when any of the drugs/agents/therapies listed above are used.  
49  
50  
51  
52  
53

#### 54 **Discontinuation of the study**

55  
56  
57 Participation of a recruited patient will be discontinued if any of the following  
58  
59  
60

1  
2  
3  
4  
5  
6 conditions is met: judged difficult to continue due to the onset of an AE; ineligibility  
7  
8  
9 confirmed after study initiation; lost to follow-up; confirmed or suspected pregnancy;  
10  
11  
12 voluntary withdrawal; repeated protocol violations; or any other reason for which the  
13  
14  
15 (sub)investigator judges that discontinuation would be necessary.  
16

17  
18 All study procedures will be discontinued if any of the following conditions is met: the  
19  
20  
21 Institutional Review Board of Juntendo University Hospital determines that the study  
22  
23  
24 should be discontinued; the appearance of safety concerns with potential impact on  
25  
26  
27 study progress; appearance of incidents or information that may potentially lead to  
28  
29  
30 impairment of ethical or scientific validity of the study; or appearance of any other  
31  
32  
33 incidents or information that may potentially lead to impairment of appropriateness of  
34  
35  
36 study conduct and/or reliability of study results.  
37  
38  
39  
40  
41

## 42 **Observations and measurements**

43  
44  
45 Patient background, medical history and complications, and data of physical  
46  
47  
48 examinations will be collected at Visit 1 (Figure 2). On final judgment regarding study  
49  
50  
51 registration at Visit 2, subjective symptoms and objective findings, medical history and  
52  
53  
54 complications, physical examinations, and vital signs will be recorded for the eligible  
55  
56  
57 patients. Subjective symptoms and objective findings will be collected twice more at  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Visits 3 and 4. Physical examinations and vital signs will also be recorded at Visit 4.

The JPAC-QOL,[21] MDS-UPDRS,[22] PDQ-39,[23] and EQ-5D-5L,[24,25] surveys and laboratory measurements (haematology and blood chemistry) will be recorded at Visits 2 and 4 (Figure 2).

Each patient will receive a Bowel Movement Diary at Visit 1 and will then record daily the status of bowel movements (date, stool hardness based on the Bristol scale,[20] and sensation of incomplete evacuation), use of rescue medication (date, dose of bisacodyl suppositories) and concomitant medication (drugs for treatment of PD-related motor symptoms; date, drug name, dose), and treatment with non-investigational drugs and/or therapy for constipation. If the patient enters the treatment period, he/she will continue to record those items and also record daily use of the investigational drug (elobixibat or placebo; date and dose, i.e. number of tablets taken) in the Diary starting at Visit 2 up to the end of study (Visit 4). Discontinuation, if it occurs, should also be recorded in the Diary with its date and reason.

### **Safety information**

This study will specifically focus on AEs that are suspected to have occurred in association with study conduct and include any of study conduct-associated events,



1  
2  
3  
4  
5  
6 impairments, deaths, infections, laboratory abnormalities, and symptoms.  
7  
8

9 The (sub)investigator will examine the patient for AEs throughout the study period  
10  
11 (Figure 2) and upon finding an event, record in the patient's eCRF its: name; onset date;  
12  
13 severity (mild, moderate, or severe); seriousness (non-serious or serious); defined  
14  
15 category of seriousness (death, life-threatening, hospitalization-initial or prolonged,  
16  
17 disability or permanent damage, an event potentially leading to disability or permanent  
18  
19 damage, ill condition judged as serious in reference to the aforementioned categories, or  
20  
21 congenital anomaly or birth defect); predictability (known or unknown); action taken  
22  
23 regarding the investigational drug (continuation, interruption, or discontinuation);  
24  
25 outcome (recovered, improving, not recovered, recovered with sequelae, died, or  
26  
27 unknown); date of outcome; causal relationship with use of the investigational drug  
28  
29 ('not related' or grades other than 'not related'; suspected factor(s) other than the  
30  
31 investigational drug should be recorded if judged 'not related').  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

#### 48 **Study population and statistical analysis**

49

50  
51 Based on the efficacy assessment of elobixibat vs. placebo in phase 2 and phase 3  
52  
53 clinical trials conducted in Japanese patients with chronic constipation,[17,31,32] the  
54  
55 expected effect size was calculated as 3.06 (5.66 for elobixibat 10 mg vs. 2.60 for  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 placebo) with a common standard deviation of 4.15. Accordingly, we estimated a  
7  
8  
9 sample size of 40 patients for each group for 90% detection power at a two-sided  
10  
11  
12 significance level of 5%. Assuming a dropout rate of 20%, we plan to recruit 100 PD  
13  
14  
15 patients with chronic constipation in this study.  
16

17  
18 The full analysis set (FAS) is defined as the randomised population receiving at least  
19  
20  
21 one dose of the investigational drug with any measurement with regard to efficacy  
22  
23  
24 assessment. To ensure the robustness of study results, we also define a per-protocol set  
25  
26  
27 (PPS) as the population after the patients are excluded from the FAS due to any of the  
28  
29  
30 following reasons: any of the inclusion criteria inapplicable or any of the exclusion  
31  
32  
33 criteria applicable; a patient receiving the investigational drug with a non-allocated drug  
34  
35  
36 number; a patient receiving prohibited concomitant medications or therapies; a patient  
37  
38  
39 deemed to be inappropriate for study participation due to low drug compliance, lost to  
40  
41  
42 follow-up, lack of measurements, etc. The safety analysis set is defined as a population  
43  
44  
45 receiving at least one dose of the investigational drug after randomization.  
46  
47

48  
49 Continuous variables and categorical variables will be presented as mean±standard  
50  
51  
52 deviation (SD) and as frequencies and percentages, respectively. Summary statistics  
53  
54  
55 may include medians and quartiles, as appropriate. Comparisons will be made for  
56  
57  
58 primary outcomes between the elobixibat group and the placebo group by analysis of  
59  
60

1  
2  
3  
4  
5  
6 covariance (ANCOVA) using baseline values and sex as covariates. Adjusted means  
7  
8  
9 with 95% confidence intervals and p values will be presented at a two-sided  
10  
11  
12 significance level of 5%. Within-group variations will be assessed by paired *t*-tests.  
13  
14  
15 Missing values will be imputed by the last observation carried forward (LOCF) method.  
16  
17  
18 Safety data will be shown as frequencies and percentages by group and individual event.  
19  
20  
21  
22  
23

## 24 **PATIENT AND PUBLIC INVOLVEMENT**

25  
26  
27 No formal patient advisory committee was established, and there was no patient or  
28  
29  
30 public involvement in the design and planning of the study.  
31  
32  
33  
34

## 35 **ETHICS AND DISSEMINATION**

36  
37  
38 This study will be conducted according to the protocol that has been prepared in  
39  
40  
41 accordance with the Helsinki Declaration, Clinical Trials Act of the Japan Ministry of  
42  
43  
44 Health, Labour and Welfare, and related laws and regulations. Each study patient will  
45  
46  
47 be anonymously identified by a specific identification code and hence protected against  
48  
49  
50 privacy invasion. The information and data of each patient will be used exclusively for  
51  
52  
53 the study purpose and will never be disseminated outside the study.  
54  
55

56 As a coordinating centre, SRD Co., Ltd. will share necessary information related to this  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 study at the participating medical organizations in this study, conduct operations aimed  
7  
8  
9 at facilitating this study, and provide support to investigators. Data management and  
10  
11  
12 monitoring are conducted by Juntendo Clinical Research and Trial Center, Juntendo  
13  
14  
15 University Hospital. Details are specified in the Data Management Plan and Monitoring  
16  
17  
18 Plan.

19  
20  
21 If a serious health hazard arises due to participation in this study, coverage benefits can  
22  
23  
24 be received from insurance carried by a principal investigator, provided, however, that  
25  
26  
27 compensation may be reduced or not compensated if it is proven that the health hazard  
28  
29  
30 was caused by the research subject's own wilful act or gross negligence. In addition, if  
31  
32  
33 there is no causal relationship between the newly occurring health hazard and the  
34  
35  
36 deterioration of the originally affected disease, it is not covered by compensation. After  
37  
38  
39 completion of the study by each research subject, the investigators will make efforts to  
40  
41  
42 provide the best medical care obtained from the results of the research.

43  
44  
45 The results obtained from this study will be disseminated through an online study  
46  
47  
48 registry, the Japan Registry of Clinical Trials (jRCT). The results will also be presented  
49  
50  
51 at relevant scientific conferences, such as a professional congress for movement  
52  
53  
54 disorders and Parkinson's disease, and in a relevant medical journal.  
55  
56  
57  
58  
59  
60

## DISCUSSION AND DISSEMINATION

PD treatment is usually focused on the amelioration of movement dysfunction.

However, patients with PD have many non-motor symptoms, especially autonomic dysfunction. Chronic constipation has been considered one of the troublesome symptoms affecting the QOL of PD patients, and it may even be life-threatening.

Although fermented milk products containing probiotics and prebiotic fibres may have a favourable effect on PD-related constipation, they will not be available as laxatives.

Although multiple classes of laxatives are available, there is little evidence supporting their use for PD-related constipation. An evidence-based medicine review[1] recommends only three drugs/foods for PD-related constipation, including macrogol, lubiprostone, and probiotics/prebiotic fibres. Two laxatives are considered “likely efficacious” and “possibly useful” for the treatment of constipation in PD patients based on the quality of randomised, controlled trials.

As mentioned above, gastrointestinal dysfunction is known to have one of the highest prevalences among the non-motor symptoms of PD. In addition, chronic constipation is known to be the earliest symptom of the prodromal phase of PD.[33] Furthermore, IBS is known to be one of the prodromal gastrointestinal symptoms[34] It has been reported that chronic constipation in PD might be caused by multiple mechanisms, including

1  
2  
3  
4  
5  
6 decreased colonic motility, reflex inability of the pelvic floor muscles during attempted  
7  
8  
9 defecation, and IBS.[2,6] However, the precise mechanisms underlying constipation  
10  
11  
12 remain unknown. Thus, the same treatment algorithm used in patients with idiopathic  
13  
14  
15 chronic constipation should be recommended for constipation occurring in the patients  
16  
17  
18 with PD.[2] Elobixibat is a highly potent selective IBAT inhibitor that results in excess  
19  
20  
21 bile acids in the colon, which is associated with increased water influx from the colon  
22  
23  
24 and colon motility via an interaction with TGR5.[15] These action mechanisms produce  
25  
26  
27 favourable effects on idiopathic chronic constipation and IBS.[17] Considering the  
28  
29  
30 effectiveness of macrogol and lubiprostone against PD-accompanying constipation,  
31  
32  
33 elobixibat is also expected to improve this condition. This study will provide the first  
34  
35  
36 evidence of whether elobixibat is a useful treatment for chronic constipation in patients  
37  
38  
39 with PD, as has already been demonstrated for idiopathic chronic constipation.  
40  
41  
42  
43  
44

45 We believe the randomised, clinical study proposed here will be useful for expanding  
46  
47  
48 treatment options for PD-related constipation in an evidence-based manner.  
49

50  
51 The study findings will be presented at relevant conferences and published in a  
52  
53  
54 peer-reviewed journal.  
55  
56  
57  
58  
59  
60

**REFERENCES**

1. Seppi K, Chaudhuri KR, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. *Mov Disord* 2019;34:180-98. <https://doi.org/10.1002/mds.27602>.
2. Fasano A, Visanji NP, Liu LWC, et al. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol* 2015;14:625-39. [https://doi.org/10.1016/S1474-4422\(15\)00007-1](https://doi.org/10.1016/S1474-4422(15)00007-1).
3. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol* 2003;2:107–16. [https://doi.org/10.1016/s1474-4422\(03\)00307-7](https://doi.org/10.1016/s1474-4422(03)00307-7).
4. Yu Q-J, Yu S-Y, Zuo L-J, et al. Parkinson disease with constipation: clinical features and relevant factors. *Scient Rep* 2018;8:567-75. <https://doi.org/10.1038/s41598-017-16790-8>.
5. Stirpe P, Hoffman M, Badiali D, et al. Constipation: an emerging risk factor for Parkinson's disease? *Eur J Neurol* 2016;23:1606–13.

1  
2  
3  
4  
5  
6 <https://doi.org/10.1111/ene.13082>.  
7  
8  
9  
10  
11

- 12 6. Mishima T, Fukae J, Fujioka S, et al. The prevalence of constipation and irritable  
13  
14 bowel syndrome in Parkinson's disease patients according to Rome III diagnostic  
15  
16 criteria. *J Parkinson's Dis* 2017;7:353-7. <https://doi.org/10.3233/JPD-160982>.  
17  
18  
19  
20  
21  
22  
23  
24 7. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-  
25  
26 based medicine review update: treatment for the non-motor symptoms of  
27  
28 Parkinson's disease. *Mov Disord* 2011;26:S42-80.  
29  
30  
31  
32  
33 <https://doi.org/10.1002/mds.23884>.  
34  
35  
36  
37  
38  
39 8. Rossi M, Merello M, Perez-Lloret S. Management of constipation in Parkinson's  
40  
41 disease. *Expert Opin Pharmacother* 2015;16: 547-57.  
42  
43  
44  
45 <https://doi.org/10.1517/14656566.2015.997211>.  
46  
47  
48  
49  
50  
51 9. Clinical Practice Guidelines for Chronic Constipation 2017 ed. by Study Group of  
52  
53 the diagnosis and treatment of chronic constipation: The Japanese Society of  
54  
55 Gastroenterology (*in Japanese*) Nankodo Co., Ltd., Tokyo Japan.  
56  
57  
58  
59  
60



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10 10. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of  
11  
12 constipation in Parkinson's disease. A randomized placebo-controlled study. *Mov*  
13  
14 *Disord* 2007;22:1239-44. <https://doi.org/10.1002/mds.21243>.  
15  
16  
17  
18  
19  
20  
21 11. Ondo WG, Kenny C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for  
22  
23 constipation associated with Parkinson disease. *Neurology* 2012;78:1650-4.  
24  
25 <https://doi.org/10.1212/WNL.0b013e3182574f28>.  
26  
27  
28  
29  
30  
31  
32  
33 12. Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for  
34  
35 constipation associated with Parkinson disease: an RCT. *Neurology*  
36  
37 2016;87:1274-80. <https://doi.org/10.1212/WNL.00000000000003127>.  
38  
39  
40  
41  
42  
43  
44  
45 13. Cassani E, Privitera G, Pezzoli G, et al. Use of probiotics for the treatment of  
46  
47 constipation in Parkinson's disease patients. *Minerva Gastroenterol Dietol*  
48  
49 2011;57:117-21.  
50  
51  
52  
53  
54  
55  
56  
57 14. Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic  
58  
59  
60

1  
2  
3  
4  
5  
6 constipation. *Therap Adv Gastroenterol* 2014;7:167-75.

7  
8  
9 <https://doi.org/10.1177/1756283X14528269>.

- 10  
11  
12  
13  
14  
15 15. Appleby RN, Walters JRF The role of bile acids in functional GI disorders.

16  
17  
18 *Neurogastroenterol Motil* 2014;26:1057-69 doi: 10.1111/nmo.12370

- 19  
20  
21  
22  
23  
24 16. Taniguchi S, Elobixibat, an ileal bile acid transporter inhibitor, induces giant

25  
26  
27 migrating contractions during natural defecation in conscious dogs,

28  
29  
30 *Neurogastroenterol Motil.* 2018;30:e13448. doi: 10.1111/nmo.13448.

- 31  
32  
33  
34  
35  
36 17. Nakajima A, Seki M, Taniguchi S, et al. Safety and efficacy of elobixibat for

37  
38  
39 chronic constipation: results from a randomised, double-blind, placebo-controlled,

40  
41  
42 phase 3 trial and an open-label, single-arm, phase 3 trial. *Lancet Gastroenterol*

43  
44  
45 *Hepatol* 2018;3:537-47. doi: 10.1016/S2468-1253(18)30123-7

- 46  
47  
48  
49  
50  
51 18. Wingate DL, Krag E, Mekhjian HS, et al. Relationships between ion and water

52  
53  
54 movement in the human jejunum, ileum and colon during perfusion with bile acids.

55  
56  
57 *Clin Sci Mol Med* 1973;45:593-606. <https://doi.org/10.1042/cs0450593>.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10 19. Bampton PA, Dinning PG, Kennedy ML, et al. The proximal colonic motor  
11  
12 response to rectal mechanical and chemical stimulation. *Am J Physiol Gastrointest*  
13  
14 *Liver Physiol* 2002;282:G443-9. <https://doi.org/10.1152/ajpgi.00194.2001>.  
15  
16  
17  
18  
19  
20 20. Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool  
21  
22 form in the general population: a prospective study. *Gut* 1992;33:818–24.  
23  
24 <https://doi.org/10.1136/gut.33.6.818>.  
25  
26  
27  
28  
29  
30 21. Nomura H, Agatsuma T, Mimura T. Validity and reliability of the Japanese version  
31  
32 of the patient assessment of constipation quality of life questionnaire. *J*  
33  
34 *Gastroenterol* 2014;49:667-73. <https://doi.org/10.1007/s00535-013-0825-y>.  
35  
36  
37  
38  
39  
40  
41  
42 22. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored  
43  
44 revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale  
45  
46 presentation and clinimetric testing results. *Movement Disord* 2008;23:2129-70.  
47  
48  
49 <https://doi.org/10.1002/mds.22340>.  
50  
51  
52  
53  
54  
55  
56  
57 23. Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

measure of functioning and well being for individuals with Parkinson's disease.

*Qual Life Res* 1995;4:241-8. <https://doi.org/10.1007/BF02260863>.

24. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727-36. <https://doi.org/10.1007/s11136-011-9903-x>.

25. Young MK, Ng S-K, Mellick G, et al. Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease. *Qual Life Res* 2013;22:1065-72. <https://doi.org/10.1007/s11136-012-0231-6>.

26. Postuma RB, Berg D, Stem M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord* 2015;30:1591-601. <https://doi.org/10.1002/mds.26424>.

27. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. *Mov Disord* 2004;19:1020-8. <https://doi.org/10.1002/mds.20213>.

- 1  
2  
3  
4  
5  
6  
7  
8  
9 28. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain  
10  
11 interaction. *Gastroenterol* 2016;150:1257-61.  
12  
13  
14  
15 <https://doi.org/10.1053/j.gastro.2016.03.035>.  
16  
17  
18  
19  
20  
21 29. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology,  
22  
23 clinical features, and Rome IV. *Gastroenterol* 2016;150:1262-79.  
24  
25  
26  
27 <https://doi.org/10.1053/j.gastro.2016.02.032>.  
28  
29  
30  
31  
32  
33 30. Pangman VC, Sloan J, Guse, L. An examination of psychometric properties of the  
34  
35 mini-mental state examination and the standardized mini-mental state examination:  
36  
37 implications for clinical practice. *Appl Nurs Res* 2000;13:209-13.  
38  
39  
40  
41  
42 <https://doi.org/10.1053/apnr.2000.9231>.  
43  
44  
45  
46  
47  
48 31. Nakajima A., Seki M., Taniguchi S. Determining an optimal clinical dose of  
49  
50 elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients  
51  
52 with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled  
53  
54  
55  
56  
57 randomized clinical trial. *J Gastroenterol* 2018;53:525-34.  
58  
59  
60

1  
2  
3  
4  
5  
6 <https://doi.org/10.1007/s00535-017-1383-5>.  
7  
8  
9

- 10  
11 32. Common Technical Document section 1.5 for Goofice 5 mg tablets by EA Pharma

12  
13  
14 Co., Ltd. (*in Japanese*)

15  
16  
17 <https://www.pmda.go.jp/drugs/2018/P20180201001/index.html>  
18  
19

- 20  
21  
22  
23 33. Kalia LV, Lang AE. Parkinson's disease. *Lancet* 2015;386:896-912

24  
25  
26 DOI:[https://doi.org/10.1016/S0140-6736\(14\)61393-3](https://doi.org/10.1016/S0140-6736(14)61393-3)  
27  
28

- 29  
30  
31  
32 34. Liu B, Sjölander A, Pedersen NL, et al. Irritable bowel syndrome and Parkinson's

33  
34  
35 disease risk: register-based studies. *npj Parkinson's Dis* 2021;7:5 DOI:

36  
37  
38 <https://doi.org/10.1038/s41531-020-00145-8>  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgements

The authors would like to thank Forte Science Communications (Tokyo, Japan) for professional assistance in preparing this manuscript.

## Authors' Contributions

TH, GO, and NH were involved in conception and trial design. TH was involved in drafting of the article. TH, GO, YS, KO, NN, JF, RN, NK, TT, YO, SS, KN, HE, AF, AN, MK, DT, TO, HTA, HK, SN, and NH were involved in critical revision of the article for important intellectual content. All the authors were involved in final approval of the article. NY provided statistical expertise.

## Data availability statement

Data are available on reasonable request (TH; thatano@juntendo.ac.jp).

## Funding

This study will be funded by EA Pharma Co., Ltd. (Tokyo) and Mochida Pharmaceutical Co., Ltd. (Tokyo) (grant number: N/A). The two companies also provide clinical supplies, the Bowel Movement Diary, and other products necessary for

1  
2  
3  
4  
5  
6 study conduct. It should be noted that the two companies and their employees will never  
7  
8  
9 be involved in any study procedures including collection, analysis or interpretation of  
10  
11  
12 data, ensuring (sub)investigators will be completely independent of the funders  
13  
14  
15 throughout study conduct.  
16

### 17 18 19 20 21 **Competing interests** 22

23  
24 There are no competing interests.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## FIGURE LEGENDS

### Figure 1 Study outline

Washout: previous medications except for anti-Parkinsonian medications will be washed out during the observation period.

Consent: written, informed consent

Exam.: physical examinations

Test: laboratory tests

Eligibility: eligibility confirmed for study participation

Alloc.: patient allocation to either treatment with elobixibat or with placebo

Prescrip.: prescription of the investigational medication according to patient allocation

Drug retrieval: unused/remaining investigational medications will be retrieved.

### Figure 2 Study schedule

<sup>a</sup>: Allowance denotes the time window allowed relative to the date of Visit 1 for Visit 2 and Visit 2 for Visits 3 and 4.

<sup>b</sup>: Temporary registration for study participation

<sup>c</sup>: Final registration for study participation

Figure 1




Figure 1 Study outline

254x190mm (307 x 307 DPI)

Figure 2

		Observation period	Administration start	Treatment period	
Visit		Visit 1	Visit 2	Visit 3	Visit 4
Date (Allowance <sup>a</sup> )		14 days prior to Visit 2	Day 1 (≤ 5 days post-Visit 2)	Day 15 post Visit 2 (± 7 days)	Day 29 post Visit 2 (≤ 7 days) or discontinuation
Informed consent		○			
Eligibility confirmation		○ (Temp. regist. <sup>b</sup> )	○ (Final regist. <sup>c</sup> )		
	Patient background	○			
	Subjective symptoms/objective findings		○	○	○
Physical examinations	History/complications	○	○		
	Physical examinations	○	○		○
	Vital signs (blood pressure/pulse rate)		○		○
	Use of investigational medication		←	→	
Bowel Movement Diary	Use of rescue/concomitant medication	←		→	
	Bowel movement	←		→	
	Other therapy for constipation	←		→	
	Adverse events	←		→	
	JPAC-QOL		○		○
	MDS-UPDRS		○		○
	PDQ-39		○		○
	EQ-5D		○		○
Laboratory tests	Haematology		○		○
	Blood chemistry		○		○

Figure 2 Study schedule

254x190mm (307 x 307 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 4 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ 4 ___
Protocol version	3	Date and version identifier	___ 10 ___
Funding	4	Sources and types of financial, material, and other support	___ 34 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 34 ___
	5b	Name and contact information for the trial sponsor	___ 34 ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ 6-8 ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ 22, 23 ___

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention \_\_6-8\_\_

4

5

6 6b Explanation for choice of comparators \_\_NA\_\_

7

8 Objectives 7 Specific objectives or hypotheses \_\_6-8\_\_

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) \_\_6-8, 10, 11\_\_

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained \_\_10\_\_

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) \_\_11, 13\_\_

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered \_\_10, 11\_\_

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) \_\_15-17\_\_

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) \_\_13-15\_\_

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial \_\_13-17\_\_

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended \_\_17, 18\_\_

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) \_\_Fig. 2\_\_

41

42

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	___19-21___
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	___19-21___
5				

### 6 **Methods: Assignment of interventions (for controlled trials)**

#### 7 Allocation:

8				
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	___13-15___
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	___13-15___
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	___13-15___
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	___13-15___
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	___13-15___
28				
29				
30				

### 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	___19-21___
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	___19-21___
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___22___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___8, 9, 10, 19-22___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___8, 9, 10___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___19-22___
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___23___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___17,18___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___10-13___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___34, 35___
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___22, 23___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___10-13___
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	___ 14 ___
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	___ NA ___
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	___ 17, 21, 22 ___
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	___ 34, 35 ___
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	___ 34 ___
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	___ 22 ___
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	___ 26 ___
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	___ 34 ___
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	___ NA ___
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary Material
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	___ NA ___
35				
36				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.



# BMJ Open

**Protocol: A multicentre, placebo-controlled, randomised, double-blind, parallel-group study investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation (CONST-PD)**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054129.R2
Article Type:	Protocol
Date Submitted by the Author:	25-Nov-2021
Complete List of Authors:	Hatano, Taku; Juntendo University, Neurology Oyama, Genko; Juntendo University Faculty of Medicine, Department of Neurology; Juntendo University Faculty of Medicine Shimo, Yasushi; Juntendo University School of Medicine, Department of Neurology Ogaki, Kotaro ; Juntendo Urayasu Hospital Nishikawa, Noriko ; Juntendo University Faculty of Medicine Fukae, Jiro ; Juntendo Nerima Hospital Nakamura, Ryota ; Juntendo Urayasu Hospital Kurita, Naohide ; Juntendo Urayasu Hospital Tsunemi , Taiji ; Juntendo University Faculty of Medicine Oji, Yutaka ; Juntendo University Faculty of Medicine Saiki, Shinji ; Juntendo University Faculty of Medicine Nishioka, Kenya ; Juntendo University Faculty of Medicine Takeshige, Haruka; Juntendo University Faculty of Medicine Taniguchi, Daisuke ; Juntendo University Faculty of Medicine Ogawa, Takashi; Juntendo University School of Medicine, Neurology Kamo, Hikaru ; Juntendo University Faculty of Medicine Eguchi, Hiroto ; Juntendo Nerima Hospital Fuse, Atsuhito ; Juntendo Nerima Hospital Nakajima, Asuka ; Juntendo Nerima Hospital Kano, Masayoshi ; Juntendo Nerima Hospital Nakajima, Sho ; Juntendo Urayasu Hospital Yanagisawa, Naotake; Juntendo University Hospital Hattori, Nobutaka ; Juntendo University Graduate School of Medicine, Neurology
<b>Primary Subject Heading</b>:	Neurology
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	Parkinson-s disease < NEUROLOGY, Motility disorders < GASTROENTEROLOGY, Clinical trials < THERAPEUTICS

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 **Protocol: A multicentre, placebo-controlled, randomised, double-blind,**  
7  
8  
9 **parallel-group study investigating the efficacy and safety of elobixibat, an ileal bile**  
10  
11 **acid transporter inhibitor, in patients with Parkinson's disease with chronic**  
12 **constipation (CONST-PD)**  
13  
14  
15  
16

17  
18  
19  
20  
21 Taku Hatano<sup>1</sup>, Genko Oyama<sup>1</sup>, Yasushi Shimo<sup>2</sup>, Kotaro Ogaki<sup>3</sup>, Noriko Nishikawa<sup>1</sup>,  
22  
23 Jiro Fukae<sup>2</sup>, Ryota Nakamura<sup>3</sup>, Naohide Kurita<sup>3</sup>, Taiji Tsunemi<sup>1</sup>, Yutaka Oji<sup>1</sup>, Shinji  
24  
25 Saiki<sup>1</sup>, Kenya Nishioka<sup>1</sup>, Haruka Takeshige-Amano<sup>1</sup>, Daisuke Taniguchi<sup>1</sup>, Takashi  
26  
27 Ogawa<sup>1</sup>, Hikaru Kamo<sup>1</sup>, Hiroto Eguchi<sup>2</sup>, Atsuhito Fuse<sup>2</sup>, Asuka Nakajima<sup>2</sup>, Masayoshi  
28  
29 Kano<sup>2</sup>, Sho Nakajima<sup>3</sup>, Naotake Yanagisawa<sup>4</sup>, Nobutaka Hattori<sup>1</sup>  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<sup>1</sup> Department of Neurology, Juntendo University Faculty of Medicine, 2-1-1 Hongo,  
Bunkyo-ku, Tokyo 113-8421, Japan

<sup>2</sup> Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai,  
Nerima-ku, Tokyo 177-8521, Japan

<sup>3</sup> Department of Neurology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka,  
Urayasu, Chiba 279-0021, Japan

<sup>4</sup> Juntendo Clinical Research and Trial Center, Juntendo University Hospital, 3-1-1,

Hongo, Bunkyo-ku, Tokyo, Japan

Correspondence to: Taku Hatano; [thatano@juntendo.ac.jp](mailto:thatano@juntendo.ac.jp) and Nobutaka Hattori;

[nhattori@juntendo.ac.jp](mailto:nhattori@juntendo.ac.jp)

**Word count:** 3913

For peer review only

## ABSTRACT

### Introduction

Chronic constipation worsens the quality of life (QOL) of Parkinson's disease (PD) patients. Elobixibat, an ileal bile acid transporter inhibitor, is a useful laxative, but its effect on chronic constipation in PD patients remains unclear. Therefore, we designed a placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of elobixibat in PD patients with chronic constipation.

### Methods and analysis

The study will consist of 2-week observation and 4-week treatment periods. Patients with clinically established PD will record the status of spontaneous bowel movements and use of rescue medications/concomitant medications in a Bowel Movement Diary from the start of the observation period at Visit 1 (Week -2). At Visit 2 (Week 0), patients will be assessed for final registration based on the Diary records and physical examinations, and allocated to either the elobixibat or placebo group. Daily intake of the investigational drug will be recorded in the Diary. Patients will undergo laboratory tests and answer constipation-related, PD-related, and QOL-related questionnaires at Visits 2 and 4 (Week 4). Subjective symptoms and objective findings will be collected at Visits 2, 3 (Week 2), and 4. Since patients' motor function might be improved by treatment of constipation, the use of dopamine preparations will also be monitored. Bowel movement data and other parameters will be compared between groups. Safety information will be collected as adverse events, specifically focusing on those occurring in association with study conduct.

## Ethics and dissemination

This study will be conducted in accordance with the Helsinki Declaration, the Clinical Trials Act of the Japan Ministry of Health, Labour and Welfare, and related laws and regulations. The study was approved by the Juntendo University Certified Review Board. The results will be disseminated through an online study registry (Japan Registry of Clinical Trials), presented at scientific conferences, and published in medical journals.

**Registration number of this study:** JPRN-jRCTs031200172 (Japan Primary Registries Network)

## Keywords

Parkinson's disease, Motility disorders, Clinical trials

### Strengths and limitations of the study

- The key strength of this study is its design as a randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of elobixibat for Parkinson's disease patients with chronic constipation.
- A further strength is that it will examine not only the efficacy of elobixibat for PD-related constipation, but also its effects on quality of life and movement in PD patients.
- Because of the short study period (4-week administration), the long-term efficacy and safety of elobixibat may not be clarified.
- Bowel Movement Diary data might have limited credibility because they are based on the patients' subjective responses.

## INTRODUCTION

Parkinson's disease (PD) is one of the most common neurodegenerative disorders.

Whereas PD is commonly considered a movement disorder, patients with PD have many difficulties with non-motor symptoms, such as dementia, anxiety, sleep disturbance, and autonomic dysfunction.[1] Chronic constipation is one of the common digestive complications experienced by PD patients even before or at an early stage of disease progression, with its frequency varying from 7% to 70% depending on the definition.[2-6] Since long-lasting constipation may decrease quality of life (QOL) and be occasionally accompanied by life-threatening intestinal perforation and/or megacolon syndrome, it should be appropriately controlled.[7,8]

Multiple types of laxatives are conventionally available for the treatment of chronic constipation, including bulk-forming agents such as carmellose sodium and dioctyl sodium sulfosuccinate, stimulants such as sennoside and sodium picosulphate hydrate, and osmotic agents such as cathartic salts (magnesium oxide and magnesium sulphate).

While stimulants and cathartic salts have been widely used, stimulants may cause intractable constipation via drug resistance if used consecutively for a long duration, and magnesium oxide may cause hypermagnesemia in elderly patients and patients with kidney malfunction.[9]



1  
2  
3  
4  
5  
6 Recently, in addition to existing osmotic agents (macrogol 4000 often in combination  
7  
8  
9 with electrolytes, movicol, lactulose), new classes of laxatives have been developed for  
10  
11  
12 chronic constipation, including epithelial function transformation drugs (lubiprostone,  
13  
14  
15 linaclotide) and an ileal bile acid transporter (IBAT) inhibitor (elobixibat).  
16

17  
18 However, the evidence for the effectiveness of laxatives either conventional or recently  
19  
20  
21 developed for the treatment of chronic constipation in PD patients is not extensive,  
22  
23  
24 except for macrogol and lubiprostone, a chloride channel-2 activator, which have been  
25  
26  
27 shown to be significantly efficacious over placebo in improving bowel movement  
28  
29  
30 frequency.[10, 11] Although probiotics and prebiotic fibre were also proposed to be  
31  
32  
33 useful for the treatment of PD-related constipation,[12, 13] more evidence for different  
34  
35  
36 classes of laxatives is needed to expand therapeutic options for chronic constipation in  
37  
38  
39 PD patients.  
40

41  
42 Elobixibat is an inhibitor of IBAT, which is expressed in the distal ileum. Bile acids  
43  
44  
45 escape the reabsorption process via the action of this drug and then enter the large  
46  
47  
48 intestinal lumen.[14] The increased levels of bile acids may interact with  
49  
50  
51 transmembrane G-protein-coupled receptor (TGR5) molecules, leading to an influx of  
52  
53  
54 water and electrolytes into the lumen. The bile acid-TGR5 interaction also triggers  
55  
56  
57 serotonin release into the intestinal wall, which activates intrinsic primary afferent  
58  
59  
60

1  
2  
3  
4  
5  
6 neurons. This leads to an interneuron-mediated activation of motor neurons that finally  
7  
8  
9 activates large-intestinal motility,[15] inducing colonic high-amplitude propagated  
10  
11  
12 contractions.[16] Recently, a large-scale, multicenter, randomized, double-blind phase 3  
13  
14  
15 study was conducted, revealing that elobixibat resolved idiopathic chronic constipation  
16  
17  
18 with no serious safety concerns.[17] Elobixibat is thus expected to be a novel option for  
19  
20  
21 the treatment of chronic constipation on the basis of its mode of action being totally  
22  
23  
24 different from those of the other existing laxatives.[18, 19]  
25

26  
27 We are planning to conduct a study to examine the efficacy and safety of elobixibat in  
28  
29  
30 PD patients with chronic constipation. The superiority of elobixibat over placebo will be  
31  
32  
33 explored in a randomized, double-blind, comparative study during 4-week daily  
34  
35  
36 administration of the drug to eligible patients. The drug will also be evaluated for its  
37  
38  
39 safety and potential impact on the underlying PD condition. The study methodology is  
40  
41  
42 detailed in this article.  
43  
44  
45  
46

## 47 **METHODS AND ANALYSIS**

48  
49  
50 The objective of this study is to explore a novel therapeutic option for chronic  
51  
52  
53 constipation in PD patients. The conduct of the present study was approved by the  
54  
55  
56 Juntendo University Certified Review Board.  
57  
58  
59  
60

### Primary endpoints

The weekly frequency of spontaneous bowel movements with no assistance from rescue therapies such as bisacodyl suppositories, enema, disimpaction, etc. (see below) will be recorded during each 7-day segment of the treatment period (Week 0-1 up to Week 3-4; see Figure 1). Bowel movements observed within 24 hours of suppository use will not be counted. Changes in the frequency at Visit 4 (Week 4) from baseline (Visit 2/Week 0; see Figure 1) will be compared between the elobixibat group and the placebo group.

### Secondary endpoints

Weekly changes from baseline in the frequency of spontaneous bowel movements and complete spontaneous bowel movements (i.e., no sensation of incomplete evacuation) will be assessed throughout the treatment period (Visit 4/Week 4; Figure 1). Changes from baseline in stool form will also be assessed up to Week 4 using the Bristol Scale.[20]

Use of rescue medication and questionnaire surveys using the Japanese version of Patient Assessment of Constipation Quality of Life (JPAC-QOL),[21] Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS),[22]

1  
2  
3  
4  
5  
6 Parkinson's Disease Questionnaire-39 (PDQ-39),[23] and Euro-Qol 5 dimension – 5  
7  
8  
9 level (EQ-5D-5L)[24,25] will be assessed. The use of dopamine preparations will also  
10  
11  
12 be monitored, since the effectiveness of elobixibat in improving constipation via  
13  
14  
15 increased levels of intestinal bile acids may also improve small intestinal absorption of  
16  
17  
18 the anti-Parkinsonian medications.  
19

20  
21 Subgroup analyses will be further performed for these endpoints by the presence or  
22  
23  
24 absence of complications, age ( $\geq$  or  $<$ 65 years), Hoehn and Yahr scale (1 to 4), duration  
25  
26  
27 of the underlying disease (PD;  $\geq$  or  $<$ median), dose equivalence of L-Dopa prior to  
28  
29  
30 elobixibat initiation, and duration of chronic constipation ( $\geq$  or  $<$ 20 years).  
31  
32  
33  
34  
35

### 36 **Overall study design**

37  
38  
39 This study is designed as a multicentre, randomised, double-blind, placebo-controlled,  
40  
41  
42 parallel-group study at 3 academic centres (Juntendo University Hospital, Juntendo  
43  
44  
45 University Urayasu Hospital, and Juntendo University Nerima Hospital), in which PD  
46  
47  
48 patients with chronic constipation will pre-prandially receive elobixibat (Goofice®; EA  
49  
50  
51 Pharma Co., Ltd., Tokyo, Japan) or its indistinguishable matched placebo once daily for  
52  
53  
54 four weeks, and the frequency of spontaneous bowel movements will be compared  
55  
56  
57 between the patients receiving either elobixibat or placebo. Safety information,  
58  
59  
60

1  
2  
3  
4  
5  
6 including adverse events (AEs) and discontinuation and interruption of the  
7  
8  
9 investigational drugs, will also be collected.  
10

11  
12 The study will consist of two periods, the observation period and the treatment period. It  
13  
14 will be conducted from October 26, 2020 (date of the first announcement in the Japan  
15  
16 Registry of Clinical Trials; jRCT) through September 30, 2022. As seen in Figure 1, we  
17  
18 plan two steps for patient registration, temporary and final. At Week -2 (Visit 1) of the  
19  
20 observation period, PD patients will be provided with detailed information about the  
21  
22 study. After providing written, informed consent for study participation, they will be  
23  
24 temporarily registered based on the patient definitions (see below). Following the  
25  
26 observation period, the patients will be further assessed for study participation at Week  
27  
28 0 (Visit 2). Once none of the exclusion criteria are confirmed to be applicable, the  
29  
30 patients will be finally registered and assigned to either the elobixibat group or the  
31  
32 placebo group in a double-blind manner (Figure 1). The eligible patients will visit their  
33  
34 clinical sites twice more (Visit 3 at Week 2 and Visit 4 at Week 4) during the 4-week  
35  
36 treatment period.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 A Bowel Movement Diary will be provided at Week -2 (Visit 1, see below) to each  
52  
53 patient, once temporarily registered. The patient will record drug use, bowel movements,  
54  
55 etc. in the Diary daily throughout the study period.  
56  
57  
58  
59  
60

## Patient definitions

Patients will be diagnosed as having PD in reference to the diagnostic criteria defined by the International Parkinson and Movement Disorder Society (MDS)[26] and must be in stages 1 to 4 on the Hoehn and Yahr scale.[27] The diagnosis of chronic constipation will be made referring to the Rome IV-defined criteria.[28,29] Outpatients aged  $\geq 20$  years at the time of informed consent must have two or more of the following symptoms related to spontaneous bowel movements from at least 6 months before consent: i)  $< 3$  spontaneous bowel movements per week; ii) straining frequency  $> 25\%$  of defecations; iii) frequency of lumpy or hard stools  $> 25\%$  of defecations; and iv) sensation of incomplete evacuation  $> 25\%$  of defecations. Patients who meet these criteria will be temporarily registered, once written, informed consent is provided (Figure 1).

A PD patient will be excluded at temporary registration if he/she: has (or is suspected to have) organic constipation or dyschezia; is unable to use a rescue medication (bisacodyl 10 mg suppositories; Teleminsoft Suppositories<sup>®</sup> 10 mg, Cox Japan, Tokyo, Japan); currently has serious kidney dysfunction (creatinine  $\geq 2.00$  mg/dL), serious hepatic dysfunction (total bilirubin  $\geq 3.0$  mg/dL, or AST or ALT  $\geq 100$  U/L), or serious cardiac

1  
2  
3  
4  
5  
6 dysfunction; has malignant tumour(s); has a history of hypersensitivity to elobixibat; is  
7  
8  
9 taking bile acid preparations (ursodeoxycholic acid, chenodeoxycholic acid),  
10  
11  
12 aluminium-containing preparations (sucralfate hydrate, aldioxa, etc.), cholestyramine,  
13  
14  
15 colestimide, digoxin, dabigatran etexilate mesylate, or midazolam; has a Mini-Mental  
16  
17  
18 State Examination (MMSE) score<sup>[30]</sup>  $\leq 26$ ; or is considered ineligible by the  
19  
20  
21 investigator or sub-investigator, hereinafter termed (sub)investigator, for study  
22  
23  
24 participation because of safety concerns, poor protocol compliance, etc. Female patients  
25  
26  
27 will also be excluded if they are pregnant, breastfeeding, or expecting pregnancy during  
28  
29  
30 the study period.

31  
32  
33 Patient exclusion is further scheduled at the final registration if one of the following  
34  
35  
36 cases applies to a patient during the 2-week observation period: use of the rescue  
37  
38  
39 medication (bisacodyl 10 mg suppositories)  $\geq 5$  times; use of the rescue medication  
40  
41  
42 within 72 hours post-bowel movement; experience of spontaneous bowel movement  
43  
44  
45 with mushy or watery stool according to Bristol Stool Form Scale type 6 or 7;<sup>[20]</sup> or  
46  
47  
48 use of prohibited medications/therapies (see below).

### 54 **Study procedures and schedule**

55  
56  
57 Registration of study patients and their allocation to the investigational drug will be  
58  
59  
60

1  
2  
3  
4  
5  
6 performed via an internet-mediated Interactive Web Response System (IWRS). The  
7  
8  
9 (sub)investigator (or study-assigned coordinator) will access the specific website for  
10  
11  
12 patient registration and allocation using a specific ID and password, and complete the  
13  
14  
15 necessary information about each anonymized patient. Investigational drug allocation  
16  
17  
18 will be instantly presented for each patient following eligibility judgment (see below).  
19

20  
21 The schedule of this study is shown in Figure 2.  
22

23  
24 The (sub)investigator will give detailed explanations of this study to each PD patient  
25  
26  
27 who meets the inclusion criteria but not the exclusion criteria at Visit 1 and then obtain  
28  
29  
30 the patient's written, informed consent on a free will basis. The patient will be informed  
31  
32  
33 that he/she may withdraw his/her consent for any reason and at any time during the  
34  
35  
36 study period. The (sub)investigator will give the eligible patient a temporary  
37  
38  
39 identification code and enter the patient's background in the Eligibility for Temporary  
40  
41  
42 Registration form of the electronic Case Report Form (eCRF; see Figures 1 and 2).  
43  
44

45 The Bowel Movement Diary and rescue medication (bisacodyl 10 mg suppositories)  
46  
47  
48 will be provided to each patient at temporary registration. The (sub)investigator will  
49  
50  
51 instruct each patient how to complete the required items in the Diary.  
52

53  
54 At Visit 2, the (sub)investigator will judge the eligibility of each patient for final  
55  
56  
57 registration referring to the exclusion criteria (see above) and enter the background of  
58  
59  
60



1  
2  
3  
4  
5  
6 qualified patients in the Eligibility for Final Registration form of the eCRF. Once the  
7  
8  
9 patient's eligibility is confirmed, a final identification code will be assigned to the  
10  
11  
12 patient, who will be then allocated randomly to treatment group.

13  
14  
15 Drug allocation will be based on a stratified, permuted block method with sex as an  
16  
17  
18 allocation factor. Satt Co., Ltd. (Tokyo) will perform the allocation by preparing a drug  
19  
20  
21 allocation table using IWRS. The study drugs will be sealed with specific drug numbers  
22  
23  
24 and delivered to the individual institutional sites according to the allocation table. At the  
25  
26  
27 final registration of patients, the (sub)investigator will check the final identification  
28  
29  
30 code and the specific number of randomly allocated investigational drug for each  
31  
32  
33 qualified patient on the IWRS screen. The specifically numbered drug will be provided  
34  
35  
36 to the patient by the (sub)investigator at Visit 2 and Visit 3 for 2 weeks each time (3  
37  
38  
39 tablets x 14 days), as described below. The key code of the allocation table will be  
40  
41  
42 opened by Satt after all study data have been locked.

43  
44  
45 The patient will start the 4-week treatment period with once-daily, preprandial intake of  
46  
47  
48 2 tablets of investigational drug (elobixibat 10 mg) or its placebo. One tablet may be  
49  
50  
51 added on the next day if no spontaneous bowel movement is observed during the next  
52  
53  
54 24 hours. If excessive effectiveness or discomfort appears, the dosage may be decreased  
55  
56  
57 at the direction of the (sub)investigator or the patient's judgment. Dose augmentation  
58  
59  
60

1  
2  
3  
4  
5  
6 from 1 tablet to 3 tablets will not be allowed. Interruption of the investigational drug  
7  
8  
9 due to the occurrence of an AE may be allowed at the direction of the (sub)investigator  
10  
11  
12 or the patient's judgment, but as-needed intake of the drug based on bowel movement  
13  
14  
15 status will not be acceptable. The drug may be restarted at the dose taken immediately  
16  
17  
18 before interruption or at a lower dose. Inappropriately long ( $\geq 7$  consecutive days) or  
19  
20  
21 frequent ( $\geq 3$  days per week during 2 consecutive weeks) interruption of the drug may  
22  
23  
24 lead to discontinuation of the patient from the study at the (sub)investigator's discretion.  
25  
26  
27  
28  
29

### 30 **Rescue and concomitant medications/therapies**

31  
32  
33 Since this study is primarily planned to explore the efficacy and safety of elobixibat as a  
34  
35  
36 laxative in PD patients, concomitant medications will be used throughout the study  
37  
38  
39 period for parkinsonism except for Duodopa<sup>®</sup> pump therapy (Abbvie Inc., North  
40  
41  
42 Chicago, IL, USA) with levodopa/carbidopa hydrate intestinal gel. Bisacodyl 10 mg  
43  
44  
45 suppositories may be used once to twice daily as a rescue medication when no bowel  
46  
47  
48 movement is observed for 72 or more consecutive hours, unless emergency use is  
49  
50  
51 required.  
52  
53

54 Because of potential effects on the study results and/or interpretation thereof, use of the  
55  
56  
57 following drugs or therapies as concomitant medications will be prohibited throughout  
58  
59  
60

1  
2  
3  
4  
5  
6 the entire study period: laxatives other than elobixibat such as magnesium hydroxide,  
7  
8  
9 sodium picosulphate, sennosides, lubiprostone, linaclotide, polyethylene glycol  
10  
11  
12 (macrogol 4000), etc.; oriental medicines for constipation (daiokanzoto extract,  
13  
14  
15 choijokito extract, daisaikoto extract, etc.); medicines indicated for irritable bowel  
16  
17  
18 syndrome (IBS; ramosetron hydrochloride, polycarbophil calcium, trimebutine maleate,  
19  
20  
21 etc.); supplements or over-the-counter drugs to improve the constipated condition;  
22  
23  
24 enema or intestinal lavage; lavage solution for colonoscopy; drugs listed in the  
25  
26  
27 Precaution section of the package insert of elobixibat (Goofice® 5 mg tablets) as “with  
28  
29  
30 caution for concomitant use” (bile acid preparations such as ursodeoxycholic acid and  
31  
32  
33 chenodeoxycholic acid, aluminium-containing antacids such as sucralfate hydrate,  
34  
35  
36 aldioxa, etc., cholestyramine, cholestimid, digoxin, dabigatran etexylate  
37  
38  
39 methanesulfonate, and midazolam; other medicines or investigational drugs being used  
40  
41  
42 in clinical trials; non-internal therapy for constipation such as biofeedback therapy;  
43  
44  
45 disimpaction; and Duodopa® pump therapy. The patient should self-report in his/her  
46  
47  
48 Bowel Movement Diary when any of the drugs/agents/therapies listed above are used.  
49  
50  
51  
52  
53

#### 54 **Discontinuation of the study**

55  
56  
57 Participation of a recruited patient will be discontinued if any of the following  
58  
59  
60

1  
2  
3  
4  
5  
6 conditions is met: judged difficult to continue due to the onset of an AE; ineligibility  
7  
8  
9 confirmed after study initiation; lost to follow-up; confirmed or suspected pregnancy;  
10  
11  
12 voluntary withdrawal; repeated protocol violations; or any other reason for which the  
13  
14  
15 (sub)investigator judges that discontinuation would be necessary.  
16  
17

18 All study procedures will be discontinued if any of the following conditions is met: the  
19  
20  
21 Institutional Review Board of Juntendo University Hospital determines that the study  
22  
23  
24 should be discontinued; the appearance of safety concerns with potential impact on  
25  
26  
27 study progress; appearance of incidents or information that may potentially lead to  
28  
29  
30 impairment of ethical or scientific validity of the study; or appearance of any other  
31  
32  
33 incidents or information that may potentially lead to impairment of appropriateness of  
34  
35  
36 study conduct and/or reliability of study results.  
37  
38  
39  
40  
41  
42

### 43 **Observations and measurements**

44  
45 Patient background, medical history and complications, and data of physical  
46  
47  
48 examinations will be collected at Visit 1 (Figure 2). On final judgment regarding study  
49  
50  
51 registration at Visit 2, subjective symptoms and objective findings, medical history and  
52  
53  
54 complications, physical examinations, and vital signs will be recorded for the eligible  
55  
56  
57 patients. Subjective symptoms and objective findings will be collected twice more at  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Visits 3 and 4. Physical examinations and vital signs will also be recorded at Visit 4.

The JPAC-QOL,[21] MDS-UPDRS,[22] PDQ-39,[23] and EQ-5D-5L[24,25] surveys and laboratory measurements (haematology and blood chemistry) will be recorded at Visits 2 and 4 (Figure 2).

Each patient will receive a Bowel Movement Diary at Visit 1 and will then record daily the status of bowel movements (date, stool hardness based on the Bristol scale,[20] and sensation of incomplete evacuation), use of rescue medication (date, dose of bisacodyl suppositories) and concomitant medication (drugs for treatment of PD-related motor symptoms; date, drug name, dose), and treatment with non-investigational drugs and/or therapy for constipation. If the patient enters the treatment period, he/she will continue to record those items and also record daily use of the investigational drug (elobixibat or placebo; date and dose, i.e. number of tablets taken) in the Diary starting at Visit 2 up to the end of study (Visit 4). Discontinuation, if it occurs, should also be recorded in the Diary with its date and reason.

### **Safety information**

This study will specifically focus on AEs that are suspected to have occurred in association with study conduct and include any of study conduct-associated events,

1  
2  
3  
4  
5  
6 impairments, deaths, infections, laboratory abnormalities, and symptoms.  
7  
8

9 The (sub)investigator will examine the patient for AEs throughout the study period  
10  
11 (Figure 2) and upon finding an event, record in the patient's eCRF its: name; onset date;  
12  
13 severity (mild, moderate, or severe); seriousness (non-serious or serious); defined  
14  
15 category of seriousness (death, life-threatening, hospitalization-initial or prolonged,  
16  
17 disability or permanent damage, an event potentially leading to disability or permanent  
18  
19 damage, ill condition judged as serious in reference to the aforementioned categories, or  
20  
21 congenital anomaly or birth defect); predictability (known or unknown); action taken  
22  
23 regarding the investigational drug (continuation, interruption, or discontinuation);  
24  
25 outcome (recovered, improving, not recovered, recovered with sequelae, died, or  
26  
27 unknown); date of outcome; causal relationship with use of the investigational drug  
28  
29 ('not related' or grades other than 'not related'; suspected factor(s) other than the  
30  
31 investigational drug should be recorded if judged 'not related').  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

#### 48 **Study population and statistical analysis**

49

50  
51 Based on the efficacy assessment of elobixibat vs. placebo in phase 2 and phase 3  
52  
53 clinical trials conducted in Japanese patients with chronic constipation,[17,31,32] the  
54  
55 expected effect size was calculated as 3.06 (5.66 for elobixibat 10 mg vs. 2.60 for  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 placebo) with a common standard deviation of 4.15. Accordingly, we estimated a  
7  
8  
9 sample size of 40 patients for each group for 90% detection power at a two-sided  
10  
11  
12 significance level of 5%. Assuming a dropout rate of 20%, we plan to recruit 100 PD  
13  
14  
15 patients with chronic constipation in this study.  
16

17  
18 The full analysis set (FAS) is defined as the randomised population receiving at least  
19  
20  
21 one dose of the investigational drug with any measurement with regard to efficacy  
22  
23  
24 assessment. To ensure the robustness of study results, we also define a per-protocol set  
25  
26  
27 (PPS) as the population after the patients are excluded from the FAS due to any of the  
28  
29  
30 following reasons: any of the inclusion criteria inapplicable or any of the exclusion  
31  
32  
33 criteria applicable; a patient receiving the investigational drug with a non-allocated drug  
34  
35  
36 number; a patient receiving prohibited concomitant medications or therapies; a patient  
37  
38  
39 deemed to be inappropriate for study participation due to low drug compliance, lost to  
40  
41  
42 follow-up, lack of measurements, etc. The safety analysis set is defined as a population  
43  
44  
45 receiving at least one dose of the investigational drug after randomization.  
46  
47

48  
49 Continuous variables and categorical variables will be presented as mean±standard  
50  
51  
52 deviation (SD) and as frequencies and percentages, respectively. Summary statistics  
53  
54  
55 may include medians and quartiles, as appropriate. Comparisons will be made for  
56  
57  
58 primary outcomes between the elobixibat group and the placebo group by analysis of  
59  
60

1  
2  
3  
4  
5  
6 covariance (ANCOVA) using baseline values and sex as covariates. Adjusted means  
7  
8  
9 with 95% confidence intervals and p values will be presented at a two-sided  
10  
11  
12 significance level of 5%. Within-group variations will be assessed by paired *t*-tests.  
13  
14  
15 Missing values will be imputed by the last observation carried forward (LOCF) method.  
16  
17  
18 Safety data will be shown as frequencies and percentages by group and individual event.  
19  
20  
21  
22  
23

## 24 **PATIENT AND PUBLIC INVOLVEMENT**

25  
26  
27 No formal patient advisory committee was established, and there was no patient or  
28  
29  
30 public involvement in the design and planning of the study.  
31  
32  
33  
34

## 35 **ETHICS AND DISSEMINATION**

36  
37  
38 This study will be conducted according to the protocol that has been prepared in  
39  
40  
41 accordance with the Helsinki Declaration, Clinical Trials Act of the Japan Ministry of  
42  
43  
44 Health, Labour and Welfare, and related laws and regulations. Each study patient will  
45  
46  
47 be anonymously identified by a specific identification code and hence protected against  
48  
49  
50 privacy invasion. The information and data of each patient will be used exclusively for  
51  
52  
53 the study purpose and will never be disseminated outside the study.  
54  
55

56 As a coordinating centre, SRD Co., Ltd. will share necessary information related to this  
57  
58  
59  
60



1  
2  
3  
4  
5  
6 study at the participating medical organizations in this study, conduct operations aimed  
7  
8  
9 at facilitating this study, and provide support to investigators. Data management and  
10  
11  
12 monitoring are conducted by Juntendo Clinical Research and Trial Center, Juntendo  
13  
14  
15 University Hospital. Details are specified in the Data Management Plan and Monitoring  
16  
17  
18 Plan.

19  
20  
21 If a serious health hazard arises due to participation in this study, coverage benefits can  
22  
23  
24 be received from insurance carried by a principal investigator, provided, however, that  
25  
26  
27 compensation may be reduced or not compensated if it is proven that the health hazard  
28  
29  
30 was caused by the research subject's own wilful act or gross negligence. In addition, if  
31  
32  
33 there is no causal relationship between the newly occurring health hazard and the  
34  
35  
36 deterioration of the originally affected disease, it is not covered by compensation. After  
37  
38  
39 completion of the study by each research subject, the investigators will make efforts to  
40  
41  
42 provide the best medical care obtained from the results of the research.

43  
44  
45 The results obtained from this study will be disseminated through an online study  
46  
47  
48 registry (Japan Registry of Clinical Trials). The results will also be presented at relevant  
49  
50  
51 scientific conferences, such as a professional congress for movement disorders and  
52  
53  
54 Parkinson's disease, and in relevant medical journals.  
55  
56  
57  
58  
59  
60

## DISCUSSION AND DISSEMINATION

PD treatment is usually focused on the amelioration of movement dysfunction.

However, patients with PD have many non-motor symptoms, especially autonomic dysfunction. Chronic constipation has been considered one of the troublesome symptoms affecting the QOL of PD patients, and it may even be life-threatening.

Although fermented milk products containing probiotics and prebiotic fibres may have a favourable effect on PD-related constipation, they will not be available as laxatives.

Although multiple classes of laxatives are available, there is little evidence supporting their use for PD-related constipation. An evidence-based medicine review[1] recommends only three drugs/foods for PD-related constipation, including macrogol, lubiprostone, and probiotics/prebiotic fibres. Two laxatives are considered “likely efficacious” and “possibly useful” for the treatment of constipation in PD patients based on the quality of randomised, controlled trials.

As mentioned above, gastrointestinal dysfunction is known to have one of the highest prevalences among the non-motor symptoms of PD. In addition, chronic constipation is known to be the earliest symptom of the prodromal phase of PD.[33] Furthermore, IBS is known to be one of the prodromal gastrointestinal symptoms.[34] It has been reported that chronic constipation in PD might be caused by multiple mechanisms, including

1  
2  
3  
4  
5  
6 decreased colonic motility, reflex inability of the pelvic floor muscles during attempted  
7  
8  
9 defecation, and IBS.[2,6] However, the precise mechanisms underlying constipation  
10  
11  
12 remain unknown. Thus, the same treatment algorithm used in patients with idiopathic  
13  
14  
15 chronic constipation should be recommended for constipation occurring in patients with  
16  
17  
18 PD.[2] Elobixibat is a highly potent selective IBAT inhibitor that results in excess bile  
19  
20  
21 acids in the colon, which is associated with increased water influx from the colon and  
22  
23  
24 colon motility via an interaction with TGR5.[15] These action mechanisms produce  
25  
26  
27 favourable effects on idiopathic chronic constipation and IBS.[17] Considering the  
28  
29  
30 effectiveness of macrogol and lubiprostone against PD-accompanying constipation,  
31  
32  
33 elobixibat is also expected to improve this condition. This study will provide the first  
34  
35  
36 evidence of whether elobixibat is a useful treatment for chronic constipation in patients  
37  
38  
39 with PD, as has already been demonstrated for idiopathic chronic constipation.  
40  
41  
42  
43  
44

45 We believe the randomised, clinical study proposed here will be useful for expanding  
46  
47  
48 treatment options for PD-related constipation in an evidence-based manner.  
49

50  
51 The study findings will be presented at relevant conferences and published in a  
52  
53  
54 peer-reviewed journal.  
55  
56  
57  
58  
59  
60

**REFERENCES**

1. Seppi K, Chaudhuri KR, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. *Mov Disord* 2019;34:180-98. <https://doi.org/10.1002/mds.27602>.
2. Fasano A, Visanji NP, Liu LWC, et al. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol* 2015;14:625-39. [https://doi.org/10.1016/S1474-4422\(15\)00007-1](https://doi.org/10.1016/S1474-4422(15)00007-1).
3. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. *Lancet Neurol* 2003;2:107–16. [https://doi.org/10.1016/s1474-4422\(03\)00307-7](https://doi.org/10.1016/s1474-4422(03)00307-7).
4. Yu Q-J, Yu S-Y, Zuo L-J, et al. Parkinson disease with constipation: clinical features and relevant factors. *Scient Rep* 2018;8:567-75. <https://doi.org/10.1038/s41598-017-16790-8>.
5. Stirpe P, Hoffman M, Badiali D, et al. Constipation: an emerging risk factor for Parkinson's disease? *Eur J Neurol* 2016;23:1606–13.

1  
2  
3  
4  
5  
6 <https://doi.org/10.1111/ene.13082>.

- 7  
8  
9  
10  
11  
12 6. Mishima T, Fukae J, Fujioka S, et al. The prevalence of constipation and irritable  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
6. Mishima T, Fukae J, Fujioka S, et al. The prevalence of constipation and irritable  
bowel syndrome in Parkinson's disease patients according to Rome III diagnostic  
criteria. *J Parkinson's Dis* 2017;7:353-7. <https://doi.org/10.3233/JPD-160982>.
7. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-  
based medicine review update: treatment for the non-motor symptoms of  
Parkinson's disease. *Mov Disord* 2011;26:S42-80.  
<https://doi.org/10.1002/mds.23884>.
8. Rossi M, Merello M, Perez-Lloret S. Management of constipation in Parkinson's  
disease. *Expert Opin Pharmacother* 2015;16: 547-57.  
<https://doi.org/10.1517/14656566.2015.997211>.
9. Clinical Practice Guidelines for Chronic Constipation 2017 ed. by Study Group of  
the diagnosis and treatment of chronic constipation: The Japanese Society of  
Gastroenterology (*in Japanese*) Nankodo Co., Ltd., Tokyo Japan.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10 10. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of  
11  
12 constipation in Parkinson's disease. A randomized placebo-controlled study. *Mov*  
13  
14 *Disord* 2007;22:1239-44. <https://doi.org/10.1002/mds.21243>.  
15  
16  
17  
18  
19  
20  
21 11. Ondo WG, Kenny C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for  
22  
23 constipation associated with Parkinson disease. *Neurology* 2012;78:1650-4.  
24  
25  
26  
27 <https://doi.org/10.1212/WNL.0b013e3182574f28>.  
28  
29  
30  
31  
32  
33 12. Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for  
34  
35 constipation associated with Parkinson disease: an RCT. *Neurology*  
36  
37 2016;87:1274-80. <https://doi.org/10.1212/WNL.00000000000003127>.  
38  
39  
40  
41  
42  
43  
44  
45 13. Cassani E, Privitera G, Pezzoli G, et al. Use of probiotics for the treatment of  
46  
47 constipation in Parkinson's disease patients. *Minerva Gastroenterol Dietol*  
48  
49 2011;57:117-21.  
50  
51  
52  
53  
54  
55  
56  
57 14. Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic  
58  
59  
60

1  
2  
3  
4  
5  
6 constipation. *Therap Adv Gastroenterol* 2014;7:167-75.

7  
8  
9 <https://doi.org/10.1177/1756283X14528269>.

- 10  
11  
12  
13  
14  
15 15. Appleby RN, Walters JRF. The role of bile acids in functional GI disorders.

16  
17  
18 *Neurogastroenterol Motil* 2014;26:1057-69. <https://doi.org/10.1111/nmo.12370>

- 19  
20  
21  
22  
23  
24 16. Taniguchi S. Elobixibat, an ileal bile acid transporter inhibitor, induces giant

25  
26  
27 migrating contractions during natural defecation in conscious dogs,

28  
29  
30 *Neurogastroenterol Motil*. 2018;30:e13448. <https://doi.org/10.1111/nmo.13448>.

- 31  
32  
33  
34  
35  
36 17. Nakajima A, Seki M, Taniguchi S, et al. Safety and efficacy of elobixibat for

37  
38  
39 chronic constipation: results from a randomised, double-blind, placebo-controlled,

40  
41  
42 phase 3 trial and an open-label, single-arm, phase 3 trial. *Lancet Gastroenterol*

43  
44  
45 *Hepatol* 2018;3:537-47. [https://doi.org/10.1016/S2468-1253\(18\)30123-7](https://doi.org/10.1016/S2468-1253(18)30123-7)

- 46  
47  
48  
49  
50  
51 18. Wingate DL, Krag E, Mekhjian HS, et al. Relationships between ion and water

52  
53  
54 movement in the human jejunum, ileum and colon during perfusion with bile acids.

55  
56  
57 *Clin Sci Mol Med* 1973;45:593-606. <https://doi.org/10.1042/cs0450593>.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10 19. Bampton PA, Dinning PG, Kennedy ML, et al. The proximal colonic motor  
11  
12 response to rectal mechanical and chemical stimulation. *Am J Physiol Gastrointest*  
13  
14 *Liver Physiol* 2002;282:G443-9. <https://doi.org/10.1152/ajpgi.00194.2001>.  
15  
16  
17  
18  
19  
20 20. Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool  
21  
22 form in the general population: a prospective study. *Gut* 1992;33:818–24.  
23  
24 <https://doi.org/10.1136/gut.33.6.818>.  
25  
26  
27  
28  
29  
30 21. Nomura H, Agatsuma T, Mimura T. Validity and reliability of the Japanese version  
31  
32 of the patient assessment of constipation quality of life questionnaire. *J*  
33  
34 *Gastroenterol* 2014;49:667-73. <https://doi.org/10.1007/s00535-013-0825-y>.  
35  
36  
37  
38  
39  
40  
41  
42 22. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored  
43  
44 revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale  
45  
46 presentation and clinimetric testing results. *Movement Disord* 2008;23:2129-70.  
47  
48  
49 <https://doi.org/10.1002/mds.22340>.  
50  
51  
52  
53  
54  
55  
56  
57 23. Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

measure of functioning and well being for individuals with Parkinson's disease.

*Qual Life Res* 1995;4:241-8. <https://doi.org/10.1007/BF02260863>.

24. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727-36. <https://doi.org/10.1007/s11136-011-9903-x>.

25. Young MK, Ng S-K, Mellick G, et al. Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease. *Qual Life Res* 2013;22:1065-72. <https://doi.org/10.1007/s11136-012-0231-6>.

26. Postuma RB, Berg D, Stem M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord* 2015;30:1591-601. <https://doi.org/10.1002/mds.26424>.

27. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. *Mov Disord* 2004;19:1020-8. <https://doi.org/10.1002/mds.20213>.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
28. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. *Gastroenterol* 2016;150:1257-61.  
<https://doi.org/10.1053/j.gastro.2016.03.035>.
29. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. *Gastroenterol* 2016;150:1262-79.  
<https://doi.org/10.1053/j.gastro.2016.02.032>.
30. Pangman VC, Sloan J, Guse, L. An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice. *Appl Nurs Res* 2000;13:209-13.  
<https://doi.org/10.1053/apnr.2000.9231>.
31. Nakajima A, Seki M, Taniguchi S. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. *J Gastroenterol* 2018;53:525-34.

1  
2  
3  
4  
5  
6  
7 <https://doi.org/10.1007/s00535-017-1383-5>.  
8  
9

- 10  
11 32. Common Technical Document section 1.5 for Goofice 5 mg tablets by EA Pharma  
12  
13  
14 Co., Ltd. (*in Japanese*)  
15

16  
17 <https://www.pmda.go.jp/drugs/2018/P20180201001/index.html>  
18  
19

- 20  
21  
22  
23 33. Kalia LV, Lang AE. Parkinson's disease. *Lancet* 2015;386:896-912.  
24

25  
26 [https://doi.org/10.1016/S0140-6736\(14\)61393-3](https://doi.org/10.1016/S0140-6736(14)61393-3)  
27  
28

- 29  
30  
31  
32 34. Liu B, Sjölander A, Pedersen NL, et al. Irritable bowel syndrome and Parkinson's  
33  
34 disease risk: register-based studies. *npj Parkinson's Dis* 2021;7:5.  
35

36  
37 <https://doi.org/10.1038/s41531-020-00145-8>  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgements

The authors would like to thank Forte Science Communications (Tokyo, Japan) for professional assistance in preparing this manuscript.

## Authors' Contributions

TH, GO, and NH were involved in conception and trial design. TH was involved in drafting of the article. TH, GO, YS, KO, NN, JF, RN, NK, TT, YO, SS, KN, HE, AF, AN, MK, DT, TO, HTA, HK, SN, and NH were involved in critical revision of the article for important intellectual content. All the authors were involved in final approval of the article. NY provided statistical expertise.

## Data availability statement

Data are available on reasonable request (TH; thatano@juntendo.ac.jp).

## Funding

This study will be funded by EA Pharma Co., Ltd. (Tokyo) and Mochida Pharmaceutical Co., Ltd. (Tokyo) (grant number: N/A). The two companies also provide clinical supplies, the Bowel Movement Diary, and other products necessary for

1  
2  
3  
4  
5  
6 study conduct. It should be noted that the two companies and their employees will never  
7  
8  
9 be involved in any study procedures including collection, analysis or interpretation of  
10  
11  
12 data, ensuring (sub)investigators will be completely independent of the funders  
13  
14  
15 throughout study conduct.  
16  
17  
18  
19  
20

### 21 **Competing interests**

22  
23  
24 There are no competing interests.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## FIGURE LEGENDS

### Figure 1 Study outline

Washout: previous medications except for anti-Parkinsonian medications will be washed out during the observation period.

Consent: written, informed consent

Exam.: physical examinations

Test: laboratory tests

Eligibility: eligibility confirmed for study participation

Alloc.: patient allocation to either treatment with elobixibat or with placebo

Prescrip.: prescription of the investigational medication according to patient allocation

Drug retrieval: unused/remaining investigational medications will be retrieved.

### Figure 2 Study schedule

<sup>a</sup>: Allowance denotes the time window allowed relative to the date of Visit 1 for Visit 2 and Visit 2 for Visits 3 and 4.

<sup>b</sup>: Temporary registration for study participation

<sup>c</sup>: Final registration for study participation

Figure 1




Figure 1 Study outline

254x190mm (307 x 307 DPI)

Figure 2

		Observation period	Administration start	Treatment period	
Visit		Visit 1	Visit 2	Visit 3	Visit 4
Date (Allowance <sup>a</sup> )		14 days prior to Visit 2	Day 1 (≤ 5 days post-Visit 2)	Day 15 post Visit 2 (± 7 days)	Day 29 post Visit 2 (≤ 7 days) or discontinuation
Informed consent		○			
Eligibility confirmation		○ (Temp. regist. <sup>b</sup> )	○ (Final regist. <sup>c</sup> )		
	Patient background	○			
	Subjective symptoms/objective findings		○	○	○
Physical examinations	History/complications	○	○		
	Physical examinations	○	○		○
	Vital signs (blood pressure/pulse rate)		○		○
	Use of investigational medication		←	→	
Bowel Movement Diary	Use of rescue/concomitant medication	←		→	
	Bowel movement	←		→	
	Other therapy for constipation	←		→	
	Adverse events	←		→	
	JPAC-QOL		○		○
	MDS-UPDRS		○		○
	PDQ-39		○		○
	EQ-5D		○		○
Laboratory tests	Haematology		○		○
	Blood chemistry		○		○

Figure 2 Study schedule

254x190mm (307 x 307 DPI)





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 4 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ 4 ___
Protocol version	3	Date and version identifier	___ 10 ___
Funding	4	Sources and types of financial, material, and other support	___ 34 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 34 ___
	5b	Name and contact information for the trial sponsor	___ 34 ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ 6-8 ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ 22, 23 ___

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention \_\_6-8\_\_

4

5

6 6b Explanation for choice of comparators \_\_NA\_\_

7

8 Objectives 7 Specific objectives or hypotheses \_\_6-8\_\_

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) \_\_6-8, 10, 11\_\_

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained \_\_10\_\_

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) \_\_11, 13\_\_

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered \_\_10, 11\_\_

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) \_\_15-17\_\_

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) \_\_13-15\_\_

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial \_\_13-17\_\_

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended \_\_17, 18\_\_

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) \_\_Fig. 2\_\_

41

42

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	___19-21___
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	___19-21___
5				

### 6 **Methods: Assignment of interventions (for controlled trials)**

#### 7 Allocation:

8				
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	___13-15___
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	___13-15___
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	___13-15___
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	___13-15___
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	___13-15___
28				
29				
30				

### 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	___19-21___
34	methods			
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	___19-21___
39				
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___22___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___8, 9, 10, 19-22___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___8, 9, 10___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___19-22___
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___23___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___17,18___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___10-13___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___34, 35___
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___22, 23___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___10-13___
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	___ 14 ___
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	___ NA ___
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	___ 17, 21, 22 ___
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	___ 34, 35 ___
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	___ 34 ___
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	___ 22 ___
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	___ 26 ___
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	___ 34 ___
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	___ NA ___
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary Material
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	___ NA ___
35				
36				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.